Alphatec (ATEC) 10-K 27 Feb 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Feb. 25, 2015	Jun. 30, 2014
Entity Information [Line Items]
Entity Registrant Name	Alphatec Holdings, Inc.
Entity Central Index Key	1350653
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Document Type	10-K
Trading Symbol	ATEC
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Amendment Flag	FALSE
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Common Stock, Shares Outstanding		99,848,142
Entity Public Float			$103.60

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Statement of Financial Position [Abstract]
Cash	$19,735	$21,345
Restricted cash	4,400	0
Current assets:
Accounts receivable, net	40,440	41,395
Inventories, net	41,747	41,939
Prepaid expenses and other current assets	5,466	7,694
Deferred income tax assets	1,324	1,372
Total current assets	113,112	113,745
Property and equipment, net	26,040	28,030
Goodwill	171,333	183,004
Intangibles, net	30,259	39,064
Other assets	4,179	1,787
Total assets	344,923	365,630
Current liabilities:
Accounts payable	10,130	10,790
Accrued expenses	35,393	62,996
Deferred revenue	1,300	1,009
Common stock warrant liabilities	8,702	0
Current portion of long-term debt	8,076	4,924
Total current liabilities	63,601	79,719
Long-term debt, less current portion	74,597	49,978
Other long-term liabilities	32,220	38,784
Deferred income tax liabilities	1,948	1,870
Redeemable preferred stock, $0.0001 par value; 20,000 authorized at December 31, 2014 and 2013; 3,319 shares issued and outstanding at both December 31, 2014 and 2013	23,603	23,603
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000 authorized; 99,856 and 97,599 shares issued and outstanding at December 31, 2014 and 2013, respectively	10	10
Treasury stock, 19 shares	-97	-97
Additional paid-in capital	413,921	403,568
Shareholder note receivable	-5,000	0
Accumulated other comprehensive income (loss)	-11,316	3,877
Accumulated deficit	-248,564	-235,682
Total stockholders’ equity	148,954	171,676
Total liabilities and stockholders’ equity	$344,923	$365,630

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Redeemable preferred stock, par value	$0.00	$0.00
Redeemable preferred stock, shares authorized	20,000,000	20,000,000
Redeemable preferred stock, shares issued	3,319,000	3,319,000
Redeemable preferred stock, shares outstanding	3,319,000	3,319,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	97,599,000	96,703,000
Common stock, shares outstanding	97,599,000	96,703,000
Treasury stock, shares	19,000	19,000

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Revenues	$206,980	$204,724	$196,278
Cost of revenues	61,834	78,669	70,761
Amortization of acquired intangible assets	1,736	1,733	1,749
Gross profit	143,410	124,322	123,768
Operating expenses:
Research and development	16,799	14,190	14,886
In-process research and development	527	0	341
Sales and marketing	77,179	76,960	75,177
General and administrative	43,381	47,949	39,939
Amortization of acquired intangible assets	2,974	3,009	2,180
Transaction related expenses	0	0	1,082
Restructuring expenses	706	9,665	0
Litigation settlement expenses	0	45,982	0
Total operating expenses	141,566	197,755	133,605
Operating income (loss)	1,844	-73,433	-9,837
Other income (expense):
Interest income	10	6	118
Interest expense	-13,616	-3,959	-6,105
Other expense, net	-33	-1,662	-794
Total other income (expense)	-13,639	-5,615	-6,781
Pretax net loss	-11,795	-79,048	-16,618
Income tax provision (benefit)	1,087	3,179	-1,159
Net loss	($12,882)	($82,227)	($15,459)
Net loss per common share:
Net loss per basic share (in dollars per share)	($0.13)	($0.85)	($0.17)
Net loss per diluted share (in dollars per share)	($0.16)	($0.85)	($0.17)
Weighted-average shares used in computing net loss per share:
Shares used in calculating basic net loss per share (in shares)	97,347	96,235	90,218
Shares used in calculating diluted net loss per share (in shares)	97,735	96,235	90,218

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement of Comprehensive Income [Abstract]
Net loss	($12,882)	($82,227)	($15,459)
Foreign currency translation adjustments	-15,193	3,765	2,924
Comprehensive loss	($28,075)	($78,462)	($12,535)

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Phygen, LLC [Member]	Common stock [Member]	Common stock [Member]	Additional paid-in capital [Member]	Additional paid-in capital [Member]	Shareholder Note Receivable [Member]	Treasury Stock [Member]	Accumulated other comprehensive income (loss) [Member]	Accumulated deficit [Member]
In Thousands, except Share data, unless otherwise specified				Phygen, LLC [Member]		Phygen, LLC [Member]
Balance beginning, value at Dec. 31, 2011	$245,328		$9		$386,224			($97)	($2,812)	($137,996)
Balance beginning, shares at Dec. 31, 2011			89,362,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,406				2,406
Exercise of stock options, value	76				76
Exercise of stock options, shares			62,000
Repurchase and/or forfeiture of common stock, value	-49				-49
Repurchase and/or forfeiture of common stock, shares			-115,000
Issuance of common stock for employee stock purchase plan, value	200				200
Issuance of common stock for employee stock purchase plan, shares			145,000
Issuance of common stock for restricted share awards granted to employees, value	0
Issuance of common stock for restricted share awards granted to employees, shares			701,000
Shares issued for consulting services, value	1,284				1,284
Shares issued for consulting services, shares			938,000
Issuance of common stock in connection with license agreements, value	250				250
Issuance of common stock in connection with license agreements, shares			139,000
Issuance of common stock in connection with acquisition, value		8,856		1		8,855
Issuance of common stock in connection with acquisition, shares				5,240,000
Issuance of common stock for equity offering, shares			231,000
Foreign currency translation adjustments	2,924								2,924
Net loss	-15,459									-15,459
Balance ending, value at Dec. 31, 2012	245,816		10		399,246			-97	112	-153,455
Balance ending, shares at Dec. 31, 2012			96,703,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,590				2,590
Exercise of stock options, value	8				8
Exercise of stock options, shares			6,000
Repurchase and/or forfeiture of common stock, value	-172				-172
Repurchase and/or forfeiture of common stock, shares			-142,000
Issuance of common stock for employee stock purchase plan, value	719				719
Issuance of common stock for employee stock purchase plan, shares			500,000
Issuance of common stock for restricted share awards granted to employees, value	0
Issuance of common stock for restricted share awards granted to employees, shares			376,000
Shares issued for consulting services, value	1,488				1,488
Shares issued for consulting services, shares			354,000
Issuance of common stock in connection with license agreements, value	250				250
Issuance of common stock in connection with license agreements, shares			130,000
Forfeiture of common stock in connection with acquisition, value		-561				-561
Forfeiture of common stock in connection with acquisition, shares				-328,000
Foreign currency translation adjustments	3,765								3,765
Net loss	-82,227
Balance ending, value at Dec. 31, 2013	171,676		10		403,568			-97	3,877	-235,682
Balance ending, shares at Dec. 31, 2013			97,599,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,690				2,690
Exercise of stock options, value	29				29
Exercise of stock options, shares	21,000		21,000
Repurchase and/or forfeiture of common stock, value	-3				-3
Repurchase and/or forfeiture of common stock, shares			-266,000
Issuance of common stock for employee stock purchase plan, value	671				671
Issuance of common stock for employee stock purchase plan, shares			608,000
Issuance of common stock for acquired technology, shares			74,000
Issuance of common stock for acquired technology, value	102				102
Issuance of common stock for restricted share awards granted to employees, shares			493,000
Shares issued for consulting services, value	1,864				1,864
Shares issued for consulting services, shares			1,327,000
Shareholder note receivable, value					5,000
Note Receivable from Shareholders for Settlement Payment							-5,000
Foreign currency translation adjustments	-15,193								-15,193
Net loss	-12,882
Balance ending, value at Dec. 31, 2014	$148,954		$10		$413,921		($5,000)	($97)	($11,316)	($248,564)
Balance ending, shares at Dec. 31, 2014			99,856,000

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating activities:
Net loss	($12,882)	($82,227)	($15,459)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	18,385	26,277	23,792
Stock-based compensation	4,554	4,078	3,690
Interest expense related to amortization of debt discount and debt issuance costs	6,700	368	919
In-process research and development	102	0	341
Provision for doubtful accounts	522	404	859
Provision for excess and obsolete inventory	3,539	11,652	6,658
Deferred income tax provision (benefit)	251	816	-3,420
Other non-cash items	1,913	1,464	2,158
Changes in operating assets and liabilities:
Restricted cash	-6,750	0	0
Accounts receivable	-1,028	-1,940	382
Inventories	-4,348	-4,407	-7,853
Prepaid expenses and other current assets	4,863	450	1,681
Other assets	-276	64	992
Accounts payable	-1,042	-3,853	-1,799
Accrued expenses and other	-35,130	55,171	-1,764
Deferred revenue	356	-510	416
Net cash (used in) provided by operating activities	-20,271	7,807	11,593
Investing activities:
Purchases of property and equipment	-11,300	-14,352	-15,646
Purchase of intangible assets	0	-750	-1,750
Cash paid for acquisitions	0	-4,000	-2,000
Cash received from sale of assets	300	0	0
Net cash used in investing activities	-11,000	-19,102	-19,396
Financing activities:
Exercise of stock options	26	8	76
Borrowings under lines of credit	163,067	154,622	121,232
Repayments under lines of credit	-156,106	-168,855	-99,853
Principal payments on capital lease obligations	-766	-434	-604
Proceeds from issuance of notes payable	30,350	28,000	0
Principal payments on notes payable	-5,837	-2,654	-12,375
Net cash provided by (used in) financing activities	30,734	10,687	8,476
Effect of exchange rate changes on cash	-1,073	-288	902
Net increase (decrease) in cash	-1,610	-896	1,575
Cash at beginning of period	21,345	22,241	20,666
Cash at end of period	19,735	21,345	22,241
Supplemental disclosure of cash flow information:
Cash paid for interest	5,885	3,973	2,592
Cash paid for income taxes	565	1,780	989
Purchases of property and equipment in accounts payable	1,638	1,513	1,367
Purchase of property and equipment through capital leases	1,212	0	2,225
Non-cash purchases of license agreements	0	250	1,000
Non-cash debt discount	650
Issuance of common stock in connection with acquisitions	0	0	8,856
Initial fair value of warrant liability	$11,280

The_Company_and_Basis_of_Prese

The Company and Basis of Presentation	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Basis of Presentation	The Company and Basis of Presentation
	The Company
	Alphatec Holdings, Inc. (“Alphatec”, “Alphatec Holdings” or the “Company”), through its wholly owned subsidiary, Alphatec Spine, Inc. and its subsidiaries (“Alphatec Spine”) designs, develops, manufactures and markets products for the surgical treatment of spine disorders. In addition to its U.S. operations, the Company also markets its products in over 50 international markets through its affiliate, Scient’x S.A.S. and its subsidiaries (“Scient’x”), via a direct salesforce in Italy and the United Kingdom and via independent distributors in the rest of Europe, the Middle East and Africa. In South America and Latin America the Company conducts its operations through its Brazilian subsidiary, Cibramed Productos Medicos. In Asia, the Company markets its products through its subsidiary, Alphatec Pacific, Inc. and its subsidiaries (“Alphatec Pacific”) via a direct sales force and independent distributors, and through distributors in other parts of Asia and Australia.
	Basis of Presentation
	The consolidated financial statements include the accounts of Alphatec and Alphatec Spine and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in the consolidated financial statements.
	The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. A going concern basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of its liabilities in the normal course of business. Based on the Company’s annual operating plan, management believes that its existing cash of $20 million combined with anticipated cash flow from operations in 2015 and other working capital of $30 million at December 31, 2014 and the Company's available borrowings under its credit facility with MidCap Financial, LLC ("MidCap") will be sufficient to fund its operating cash requirements through at least December 31, 2015.
	The Company’s Amended and Restated Credit, Security and Guaranty Agreement (the “Credit Facility”) with MidCap contains financial covenants consisting of a monthly fixed charge coverage ratio, a senior leverage ratio and a total leverage ratio (see Note 6). Based on the Company’s board-approved current operating plan, the Company believes that it will be in compliance with the financial covenants of the Credit Facility at least through December 31, 2015. However, there is no assurance that the Company will be able to do so. If the Company is not able to achieve its planned revenue or incurs costs in excess of its forecasts, it may be required to substantially reduce discretionary spending and it could be in default of the Credit Facility which would require a waiver from MidCap. There can be no assurance that such a waiver could be obtained, that the Credit Facility could be successfully renegotiated or that the Company can modify its operations to maintain liquidity. If the Company is unable to obtain any required waivers or amendments, MidCap would have the right to exercise remedies specified in the Credit Facility, including accelerating the repayment of debt obligations. The Company may be forced to seek additional financing, which may include additional debt and/or equity financing or funding through other third party agreements. There can be no assurances that additional financing will be available on acceptable terms or available at all. Furthermore, any equity financing may result in dilution to existing stockholders and any debt financing may include restrictive covenants.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts in the Company’s consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
	Concentrations of Credit Risk and Significant Customers
	Financial instruments, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and accounts receivable. The Company limits its exposure to credit loss by depositing its cash with established financial institutions. As of December 31, 2014 a substantial portion of the Company’s available cash funds is held in business accounts. Although the Company deposits its cash with multiple financial institutions, its deposits, at times, may exceed federally insured limits.
	The Company’s customers are primarily hospitals, surgical centers and distributors and no single customer represented greater than 10 percent of consolidated revenues for any of the periods presented. Credit to customers is granted based on an analysis of the customers’ credit worthiness and credit losses have not been significant.
	Revenue Recognition
	The Company derives its revenues primarily from the sale of spinal surgery implants used in the treatment of spine disorders. The Company sells its products primarily through its direct sales force and independent distributors. Revenue is recognized when all four of the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectability is reasonably assured. In addition, the Company accounts for revenue under provisions which set forth guidelines for the timing of revenue recognition based upon factors such as passage of title, installation, payment and customer acceptance.
	The Company’s revenue from sales of spinal and other surgical implant products is recognized upon receipt of written acknowledgment that the product has been used in a surgical procedure or upon shipment to third-party customers who immediately accept title to such product.
	Deferred revenues consist of sales transactions where circumstances indicate that colectibility is not reasonably assured due to payment terms, regional market risks or customer history. The Company defers the recognition of revenue until payments become due and cash is received from these distributors. As of December 31, 2014 and 2013, the balance in deferred revenue totaled $1.3 million and $1.0 million, respectively.
	Restricted Cash
	In March and November 2014, the Company borrowed and set aside cash for the payment of a portion of the Orthotec litigation settlement, which is subject to the terms of the facility agreement that it entered into with Deerfield on March 17, 2014. The Company classified this cash as restricted, because it may not be used for purposes other than payments of amounts due under the Orthotec litigation settlement agreement. As of December 31, 2014, the Company had $4.4 million classified as short-term restricted cash and $2.4 million classified as long-term restricted cash in other assets.
	Accounts Receivable
	Accounts receivable are presented net of allowance for doubtful accounts. The Company makes judgments as to its ability to collect outstanding receivables and provides allowances for a portion of receivables when collection becomes doubtful. Provisions are made based upon a specific review of all significant outstanding invoices and the overall quality and age of those invoices not specifically reviewed. In determining the provision for invoices not specifically reviewed, the Company analyzes historical collection experience. If the historical data used to calculate the allowance provided for doubtful accounts does not reflect the Company’s future ability to collect outstanding receivables or if the financial condition of customers were to deteriorate, resulting in impairment of their ability to make payments, an increase in the provision for doubtful accounts may be required.
	Inventories
	Inventories are stated at the lower of cost or market, with cost primarily determined under the first-in, first-out method. The Company reviews the components of inventory on a periodic basis for excess, obsolete and impaired inventory, and records a reserve for the identified items. The Company calculates an inventory reserve for estimated excess and obsolete inventory based upon historical turnover and assumptions about future demand for its products and market conditions. The Company’s biologics inventories have an expiration based on shelf life and are subject to demand fluctuations based on the availability and demand for alternative implant products. The Company’s estimates and assumptions for excess and obsolete inventory are reviewed and updated on a quarterly basis. Increases in the reserve for excess and obsolete inventory result in a corresponding increase to cost of revenues and establish a new cost basis for the part. Approximately $17.3 million and $18.4 million of inventory was held at consigned locations as of December 31, 2014 and 2013, respectively.
	Property and Equipment
	Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, generally ranging from three to seven years. Leasehold improvements and assets acquired under capital leases are amortized over the shorter of their useful lives or the terms of the related leases.
	Goodwill and Other Intangible Assets
	The Company accounts for goodwill and other intangible assets in accordance with provisions which require that goodwill and other identifiable intangible assets with indefinite useful lives be tested for impairment at least annually. The Company tests goodwill and intangible assets for impairment in December of each year, or more frequently if events and circumstances warrant. These assets are impaired if the Company determines that their carrying values may not be recoverable based on an assessment of certain events or changes in circumstances. If the assets are considered to be impaired, the Company recognizes the amount by which the carrying value of the assets exceeds the fair value of the assets as an impairment loss. During the year ended December 31, 2013, the Company decided that it would not continue to market an adult stem cell product sold under the Company's private label name of PureGen. The Company also decided that it would no longer actively market two additional products. The Company expensed $1.3 million as impairment charges in cost of goods sold in the year ended December 31, 2013 for the write-off of intangible assets related to these products.
	The Company estimated the fair value in step one of the goodwill impairment test based on a combination of the income approach which included discounted cash flows as well as a market approach that utilized the Company’s market information. The income approach fair value measurements are categorized within Level 3 of the fair value hierarchy. The Company’s discounted cash flows required management judgment with respect to forecasted sales, launch of new products, gross margin, selling, general and administrative expenses, capital expenditures and the selection and use of an appropriate discount rate and terminal rate. For purposes of calculating the discounted cash flows, the Company used estimated revenue growth rates averaging between 4% and 7% for the discrete forecast period. Cash flows beyond the discrete forecasts were estimated using a terminal value calculation, which incorporated historical and forecasted financial trends and considered long-term earnings growth rates for publicly traded peer companies. Future cash flows were then discounted to present value at a discount rate of 11.5%, and terminal value growth rate of 4%. Publicly available information regarding comparable market capitalization was also considered in assessing the reasonableness of the Company’s fair value. The Company’s assessment resulted in a fair value that was greater than the Company’s carrying value at December 31, 2014. In accordance with the authoritative literature, the second step of the impairment test was not required to be performed and thus no impairment of goodwill was recorded as of December 31, 2014.
	Significant management judgment is required in the forecast of future operating results that are used in the Company’s impairment analysis. The estimates the Company used are consistent with the plans and estimates that it uses to manage its business. Significant assumptions utilized in the Company’s income approach model included the growth rate of sales for recently introduced products and the introduction of anticipated new products similar to its historical growth rates. Another important assumption involved in forecasted sales is the projected mix of higher margin U.S. based sales and lower margin non-U.S. based sales. Additionally, the Company has projected an improvement in its gross margin, similar to its historical improvement in gross margins, as a result of its forecasted mix in U.S. sales versus non-U.S. sales and lower manufacturing cost per unit based on the increase in forecasted volume to absorb applied overhead over the next ten years. Although the Company believes its underlying assumptions supporting this assessment are reasonable, if the Company’s forecasted sales, mix of product sales, growth rates of recently introduced new products, timing of and growth rates of new product introductions, gross margin, selling, general and administrative expenses, or the discount rate vary from its forecasts, the Company could be exposed to material impairment charges in the future. Additionally, if the Company’s stock price decreases significantly from the closing price on December 31, 2014, the Company may be required to perform an interim analysis in 2015 that could result in an impairment charge.
	The accounting provisions also require that intangible assets with definite useful lives be amortized over their respective estimated useful lives and reviewed for indicators of impairment. The Company is amortizing its intangible assets, other than goodwill, on a straight-line basis over a one to fifteen-year period.
	Impairment of Long-Lived Assets
	The Company assesses potential impairment to its long-lived assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the carrying amount of the long-lived assets is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Any required impairment loss is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value and is recorded as a reduction in the carrying value of the related asset and a charge to operating results.
	Foreign Currency
	The Company’s results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates. The Company’s primary functional currency is the U.S. dollar, while the functional currency of the Company’s foreign subsidiaries are the Japanese Yen, the Euro, the Brazilian Real, the British Pound and the Hong Kong dollar. Assets and liabilities denominated in foreign currencies are translated at the rate of exchange on the balance sheet date. Revenues and expenses are translated using the average exchange rate for the period. Net gains and losses resulting from the translation of foreign financial statements are recorded as accumulated other comprehensive income (loss) in stockholders’ equity. Net foreign currency gains or (losses) resulting from transactions in currencies other than the functional currencies are included in other income (expense), net in the accompanying consolidated statements of operations. For the years ended December 31, 2014, 2013 and 2012, the Company recorded net foreign currency losses of approximately $1.0 million, $1.7 million and $0.9 million, respectively.
	Warrants to Purchase Common Stock
	Common stock warrants that contain compliance covenants and cash payment obligations are classified as common stock warrant liabilities on the consolidated balance sheet. The Company records the warrant liability at fair value and adjusts the carrying value of these common stock warrants to their estimated fair value at each reporting date with the increases or decreases in the fair value of such warrants at each reporting date recorded as other income (expense) in the consolidated statement of operations.
	Fair Value Measurements
	The carrying amount of financial instruments consisting of cash, restricted cash, trade accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses, accrued compensation and current portion of long-term debt included in the Company’s consolidated financial statements are reasonable estimates of fair value due to their short maturities. Based on the borrowing rates currently available to the Company for loans with similar terms, management believes the fair value of long-term debt approximates its carrying value.
	Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level 1:	Observable inputs such as quoted prices in active markets;
	Level 2:	Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3:	Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	The Company does not maintain any financial instruments that are considered to be Level 1 or Level 2 instruments as of December 31, 2014 or December 31, 2013. The Company classifies its common stock warrant liabilities within Level 3 of the fair value hierarchy because they are valued using valuation models with significant unobservable inputs. The following table provides a reconciliation of liabilities measured at fair value using significant unobservable inputs (Level 3) for the year ended December 31, 2014 (in thousands):
		Common Stock Warrant Liabilities
	Balance at December 31, 2013	$	—
	Issuance	11,280
	Changes in fair value	(2,578		)
	Balance at December 31, 2014	$	8,702
	Common stock warrant liabilities are measured at fair value using the Black-Scholes option pricing valuation model. The assumptions used in the Black-Scholes option pricing valuation model for the common stock warrant liabilities were: (a) a risk-free interest rate based on the rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the remaining contractual term of the warrants; (b) an assumed dividend yield of zero based on the Company’s expectation that it will not pay dividends in the foreseeable future; (c) an expected term based on the remaining contractual term of the warrants; and (d) an expected volatility based upon the Company's historical volatility over the remaining contractual term of the warrants. The significant unobservable input used in measuring the fair value of the common stock warrant liabilities associated with the Deerfield Facility Agreement (defined below) is the expected volatility. Significant increases in volatility would result in a higher fair value measurement. The decrease in the fair value of the common stock warrant liabilities as of December 31, 2014 was primarily driven by the decrease in the Company's common stock price at December 31, 2014 as compared to the Company's common stock price on March 17, 2014 and March 20, 2014, the dates when the common stock warrants to purchase 10.3 million shares of the Company's common stock were issued. There was no change in the fair value of the warrants to purchase 1.2 million shares of the Company's common stock issued on November 21, 2014.
	Research and Development
	Research and development expense consists of costs associated with the design, development, testing, and enhancement of the Company’s products. Research and development costs also include salaries and related employee benefits, research-related overhead expenses, fees paid to external service providers, and costs associated with the Company’s Scientific Advisory Board and Executive Surgeon Panels. Research and development costs are expensed as incurred.
	In-Process Research and Development
	In-process research and development (“IPR&D”) consists of acquired research and development assets that are not part of an acquisition of a business and were not technologically feasible on the date the Company acquired them and had no alternative future use at that date or assets acquired in a business acquisition that are determined to have no alternative future use. The Company expects all acquired IPR&D will reach technological feasibility, but there can be no assurance that commercial viability of these products will ever be achieved. The nature of the efforts to develop the acquired technologies into commercially viable products consists principally of planning, designing, developing and testing products in order to obtain regulatory approvals. If commercial viability were not achieved, the Company would likely look to other alternatives to provide these products. Until the technological feasibility of the acquired research and development assets are established, the Company expenses these costs.
	Leases
	The Company leases its facilities and certain equipment and vehicles under operating leases, and certain equipment under capital leases. For facility leases that contain rent escalation or rent concession provisions, the Company records the total rent payable during the lease term on a straight-line basis over the term of the lease. The Company records the difference between the rent paid and the straight-line rent as a deferred rent liability in the accompanying consolidated balance sheets.
	Product Shipment Cost
	Product shipment costs are included in sales and marketing expense in the accompanying consolidated statements of operations. Product shipment costs totaled $3.7 million, $3.1 million and $2.9 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	Stock-Based Compensation
	The Company accounts for stock-based compensation under provisions which require that share-based payment transactions with employees be recognized in the financial statements based on their fair value and recognized as compensation expense over the vesting period. The amount of expense recognized during the period is affected by subjective assumptions, including: estimates of the Company’s future volatility, the expected term for its stock options, the number of options expected to ultimately vest, and the timing of vesting for the Company’s share-based awards.
	The Company uses a Black-Scholes option-pricing model to estimate the fair value of its stock option awards. The calculation of the fair value of the awards using the Black-Scholes option-pricing model is affected by the Company’s common stock price on the date of grant as well as assumptions regarding the following:
	•	Estimated volatility is a measure of the amount by which the Company’s common stock price is expected to fluctuate each year during the expected life of the award. The Company’s estimated volatility through December 31, 2014 was based on a weighted-average volatility of its actual historical volatility over a period equal to the expected life of the awards.
	•	The expected term represents the period of time that awards granted are expected to be outstanding. Through December 31, 2014, the Company calculated the expected term using a weighted-average term based on historical exercise patterns and the term from option date to full exercise for the options granted within the specified date range.
	•	The risk-free interest rate is based on the yield curve of a zero-coupon U.S. Treasury bond on the date the stock option award is granted with a maturity equal to the expected term of the stock option award.
	•	The assumed dividend yield is based on the Company’s expectation of not paying dividends in the foreseeable future.
	The Company used historical data to estimate the number of future stock option forfeitures. Share-based compensation recorded in the Company’s consolidated statement of operations is based on awards expected to ultimately vest and has been reduced for estimated forfeitures. The Company’s estimated forfeiture rates may differ from its actual forfeitures which would affect the amount of expense recognized during the period.
	The Company accounts for stock option grants to non-employees in accordance with provisions which require that the fair value of these instruments be recognized as an expense over the period in which the related services are rendered.
	Share-based compensation expense of awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met. Determining the likelihood and timing of achieving performance conditions is a subjective judgment made by management which may affect the amount and timing of expense related to these share-based awards. Share-based compensation is adjusted to reflect the value of options which ultimately vest as such amounts become known in future periods.
	Valuation of Stock Option Awards
	The assumptions used to compute the share-based compensation costs for the stock options granted during the years ended December 31, 2014, 2013 and 2012 are as follows:
		Year Ended December 31,
		2014			2013			2012
Risk-free interest rate	1.8-1.9%			1.1-1.8%			0.9-1.2%
Expected dividend yield	—			—			—
Weighted average expected life (years)	5.4-5.5			5.3-5.5			5.3-5.8
Volatility	60-71%			75-76%			75-78%
Compensation Costs
The compensation cost that has been included in the Company’s consolidated statement of operations for all stock-based compensation arrangements is detailed as follows (in thousands):
	Year Ended December 31,
	2014				2013			2012
Cost of revenues	$	274			$	228		$	137
Research and development	2,080				719			261
Sales and marketing	470				459			1,695
General and administrative	1,730				2,672			1,447
Total	$	4,554			$	4,078		$	3,540
The amounts provided above include stock-based compensation expense of $1.9 million, $1.5 million and $1.3 million during the years ended December 31, 2014, 2013 and 2012, respectively, related to the vesting of stock options and awards granted to non-employees under consulting agreements.
Income Taxes
The Company accounts for income taxes in accordance with provisions which set forth an asset and liability approach that requires the recognition of deferred tax assets and deferred tax liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. In making such determination, a review of all available positive and negative evidence must be considered, including scheduled reversal of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance.
The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision.
Net Loss per Share
Basic earnings per share (“EPS”) is calculated by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted EPS is computed by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period and the weighted average number of dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, common stock subject to repurchase by the Company and options are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share when their effect is dilutive. (In thousands, except per share data):
	Year Ended December 31,
	2014				2013			2012
Numerator:
Net loss for basic earnings per share	$	(12,882	)		$	(82,227	)	$	(15,459	)
Decrease in fair value of warrants	(2,578		)		—			—
Diluted net loss applicable to common stockholders	$	(15,460	)		$	(82,227	)	$	(15,459	)
Denominator:
Weighted average common shares outstanding	98,138				97,111			90,870
Weighted average unvested common shares subject to repurchase	(791		)		(876		)	(652		)
Weighted average common shares outstanding—basic	97,347				96,235			90,218
Effect of dilutive securities:
Conversion of preferred stock	—				—			—
Options	—				—			—
Warrants	388				—			—
Weighted average common shares outstanding—diluted	97,735				96,235			90,218
Net loss per share:
Basic	$	(0.13	)		$	(0.85	)	$	(0.17	)
Diluted	$	(0.16	)		$	(0.85	)	$	(0.17	)
As of December 31, 2014, 2013 and 2012, none of the outstanding shares of redeemable preferred stock were convertible to common stock.
The weighted-average anti-dilutive securities not included in diluted net loss per share were as follows (in thousands):
	Year Ended December 31,
	2014			2013			2012
Options to purchase common stock	7,057			4,597			4,621
Warrants to purchase common stock	725			594			476
Unvested restricted stock awards	791			876			652
	8,573			6,067			5,749
Recent Accounting Pronouncements
In March 2013, the Financial Accounting Standards Board (“FASB”) issued guidance on a parent company’s accounting for the cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. This new guidance requires that the parent release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. The amendments became effective for the Company beginning January 1, 2014. The Company adopted this guidance and the adoption did not have any impact on the Company's financial statements.
In April 2014, the FASB issued new guidance related to reporting discontinued operations. This new standard raises the threshold for a disposal to qualify as a discontinued operation and requires new disclosures of both discontinued operations and certain other disposals that do not meet the definition of a discontinued operation. The new standard is effective for fiscal years beginning on or after December 15, 2014. The Company is evaluating the impact, if any, of adopting this new accounting standard on its financial statements.
In May 2014, the FASB issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for the Company beginning January 1, 2017 and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is evaluating the impact of adopting this new accounting standard on its financial statements.
In August 2014, the FASB issued guidance related to disclosures of uncertainties about an entity’s ability to continue as a going concern. The guidance requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued. Management will be required to make this evaluation for both annual and interim reporting periods and will have to make certain disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the entity’s ability to continue as a going concern. Substantial doubt exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued. The guidance is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter 2017, with early adoption permitted. The Company is evaluating the impact of this guidance and expects to adopt the standard for the annual reporting period ending December 31, 2016.

Acquisitions_and_Investment

Acquisitions and Investment	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Acquisitions and Investment	Acquisitions and Investment
	Acquisition of Phygen, LLC
	On November 6, 2012, the Company closed the acquisition pursuant to the Asset Purchase Agreement (the “Asset Purchase Agreement”) with Phygen, LLC (“Phygen”), pursuant to which the Company agreed to purchase Phygen’s right, title and interest in, and certain assets used by, Phygen in connection with the design, development, marketing and distribution of certain of Phygen’s spinal implant products, together with the intellectual property rights, contractual rights, inventories and certain liabilities related thereto. At the closing of the transaction, the Company issued to Phygen 4,069,087 unregistered shares of the Company’s common stock and paid to Phygen $2 million in cash. The Company placed 1,170,960 of such unregistered shares of the Company's common stock into an escrow account, which served as security against any potential indemnification obligations of Phygen under the Asset Purchase Agreement for a period of 12 months following the closing. In November 2013, the Company made a claim of 328,356 shares of the Company's common stock against the escrow shares, which were returned to the Company in December 2013. In connection with this release of shares the Company recorded income of $0.6 million as a reduction of general and administrative expenses in the year ended December 31, 2013. The remaining 842,604 shares of the Company's common stock held in escrow were released to the owners of Phygen. In addition, pursuant to the Asset Purchase Agreement, the Company paid to Phygen $4 million in cash in April 2013. In connection with the Phygen acquisition, the Company incurred transaction related expenses of $1.1 million in the year ended December 31, 2012. The results of Phygen’s operations are included in the consolidated financial statements from November 7, 2012.
	Based on the closing price of Alphatec’s common stock of $1.69 per share on November 6, 2012, cash consideration and contingent liabilities, the total purchase price of the Phygen acquisition of $18.5 million consisted of cash consideration of $5.9 million, fair value of Alphatec common stock of $8.9 million and contingent consideration of $3.7 million.
	Pro forma supplemental financial information is not provided as the impact of the Phygen acquisition was not material to operating results in the year ended December 31, 2014, 2013 or 2012.

Balance_Sheet_Details

Balance Sheet Details	12 Months Ended
	Dec. 31, 2014
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Details	Balance Sheet Details
	Accounts Receivable
	Accounts receivable consist of the following (in thousands):
		December 31,
		2014				2013
	Accounts receivable	$	41,233			$	42,443
	Allowance for doubtful accounts	(793		)		(1,048		)
	Accounts receivables, net	$	40,440			$	41,395
	Inventories
	Inventories consist of the following (in thousands):
		31-Dec-14										31-Dec-13
		Gross				Reserve for				Net		Gross		Reserve for			Net
						excess and								excess and
						obsolete								obsolete
	Raw materials	$	5,020			$	—			$	5,020	$	4,375	$	—		$	4,375
	Work-in-process	1,032				—				1,032		531		—			531
	Finished goods	57,020				(21,325		)		35,695		60,979		(23,946		)	37,033
	Inventories	$	63,072			$	(21,325	)		$	41,747	$	65,885	$	(23,946	)	$	41,939
	Property and Equipment
	Property and equipment consist of the following (in thousands):
		Useful lives		December 31,
		(in years)		2014				2013
	Surgical instruments	4		$	62,872			$	62,636
	Machinery and equipment	7		15,382				14,692
	Computer equipment	3		3,180				3,357
	Office furniture and equipment	5		3,789				3,703
	Leasehold improvements	various		3,841				4,161
	Building	39		65				52
	Land	n/a		9				10
	Construction in progress	n/a		1,320				1,228
				90,458				89,839
	Less accumulated depreciation and amortization			(64,418		)		(61,809		)
	Property and equipment, net			$	26,040			$	28,030
	Total depreciation expense was $12.2 million, $14.6 million and $14.2 million for the years ended December 31, 2014, 2013 and 2012, respectively. At December 31, 2014, assets recorded under capital leases of $3.2 million were included in the machinery and equipment balance and $0.6 million are included in the construction in progress balance. At December 31, 2013, assets recorded under capital leases of $1.8 million were included in the machinery and equipment balance and $0.6 million are included in the construction in progress balance. Amortization of assets under capital leases is included in depreciation expense.
	Intangible Assets
	Intangibles assets consist of the following (in thousands):
		Useful lives		December 31,
		(in years)		2014				2013
	Developed product technology	8-Mar		$	22,526			$	23,633
	Distribution rights	3		2,095				2,343
	Intellectual property	5		1,004				1,004
	License agreements	7-Jan		16,716				17,686
	Core technology	10		4,554				5,137
	Trademarks and trade names	9-Mar		3,559				3,920
	Customer-related	15-Dec		20,493				22,161
	Distribution network	12-Oct		4,027				4,027
	Physician education programs	10		2,802				3,160
	Supply agreement	10		225				225
				78,001				83,296
	Less accumulated amortization			(47,742		)		(44,232		)
	Intangible assets, net			$	30,259			$	39,064
	Total amortization expense was $6.2 million, $11.6 million and $9.6 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	During the year ended December 31, 2013, the Company decided that it would not continue to market an adult stem cell product sold under the Company's private label name of PureGen. The Company also decided that it would no longer actively market two additional products. The Company expensed $1.3 million as impairment charges in cost of goods sold in the year ended December 31, 2013 for the write-off of intangible assets related to these products.
	The future expected amortization expense related to intangible assets as of December 31, 2014 is as follows (in thousands):
	Year Ending December 31,
	2015	$	5,646
	2016	5,163
	2017	4,866
	2018	3,053
	2019	2,852
	Thereafter	8,679
	Total	$	30,259
	Accrued Expenses
	Accrued expenses consist of the following (in thousands):
	December 31,
	2014				2013
Legal	$	967			$	2,139
Accounting	1,262				928
Severance	318				297
Restructuring	531				9,170
Sales milestones	107				1,828
Accrued taxes	1,344				1,120
Deferred rent	785				1,163
Royalties	2,129				2,347
Commissions	6,152				6,180
Payroll and related	8,291				9,369
Litigation settlements	7,393				22,600
Accrued interest	946				—
Other	5,168				5,855
Total accrued expenses	$	35,393			$	62,996
Goodwill
The changes in the carrying amount of goodwill from December 31, 2013 through December 31, 2014 were as follows (in thousands):
	2014				2013
Balance at January 1,	$	183,004			$	180,838
Change in Phygen goodwill	—				(1,610		)
Effect of foreign exchange rate on goodwill	(11,671		)		3,776
Balance at December 31,	$	171,333			$	183,004

License_and_Consulting_Agreeme

License and Consulting Agreements	12 Months Ended
	Dec. 31, 2014
License and Consulting Agreements [Abstract]
License and Consulting Agreements	License and Consulting Agreements
	OsseoFix Spinal Fracture Reduction System License Agreement
	On April 16, 2009, the Company and Stout Medical Group LP (“Stout”) amended the license agreement that the parties had entered into in September 2007 (the “License Amendment”) that provides the Company with a worldwide license to develop and commercialize Stout’s proprietary intellectual property related to a treatment for vertebral compression fractures. The effective date of the License Amendment is March 31, 2009. Under the License Amendment, the timing of the minimum royalty payments has been adjusted and Stout’s ability to terminate the License Amendment was revised. Under the original license agreement, the Company’s minimum royalty obligation began in the year ending December 31, 2009 and there are milestones due upon attainment of sales volumes. Pursuant to the License Amendment, the minimum royalty obligation is suspended until a licensed product obtains regulatory approval from the United States Food and Drug Administration (the “FDA”). In addition, under the terms of the License Amendment, Stout has the ability to terminate the License Amendment if the Company is not using commercially reasonable efforts to obtain regulatory approval to market and sell a licensed product; provided that the Company has the right to delay such termination in exchange for making certain payments to Stout. If, during the time period when such payments are made, the Company were to make a regulatory filing for the marketing and sale of a licensed product, such termination will be null and void. Pursuant to the License Amendment, Stout is entitled to retain all up-front payments that had been previously paid to it. The other material terms of the license agreement were not changed in the License Amendment.
	In August 2014, the Company entered a third amendment (the “Third Amendment”) to the License Agreement. Pursuant to the Third Amendment: (i) the royalty rate paid by the Company for the net sales of licensed products is a fixed amount per quarter through December 31, 2016; (ii) the royalty rate starting in 2017 will be increased from 7.0% to 8.5%; (ii) starting in 2017, the minimum royalty obligation is $0.2 million per year, with such minimum royalty obligation being further reduced stating in 2018; (iii) the territory is amended so that the United States is removed from the territory in which the Company can sell and market licensed products; (iv) all obligations of the Company to pursue a clinical trial in the United States are deleted; and (v) all milestone payments based on the achievement of certain sales milestones are deleted. In connection with this amendment the Company reversed the $1.7 million accrual it had recorded for the sales milestone payment into cost of goods sold for the year ended December 31, 2014.
	OsseoScrew License Agreement
	In December 2007, the Company entered into an exclusive license agreement (the “OsseoScrew License Agreement”), with Progressive Spinal Technologies LLC (“PST”), which provides the Company with an exclusive worldwide license to develop and commercialize PST’s proprietary intellectual property related to an expanding pedicle screw with increased pull-out strength. The financial terms of the OsseoScrew License Agreement include: (i) a cash payment payable following the execution of the agreement; (ii) development and sales milestone payments in cash and the Company’s common stock that began to be achieved and paid in 2008; and (iii) a royalty payment based on net sales of licensed products. The agreement included milestone payments of $3.6 million consisting of cash and the Company’s common stock upon the completion of the biomechanical testing, which were attained in 2009. Furthermore, the agreement includes milestone payments of $2.5 million consisting of cash and the Company’s common stock upon market launch.
	In November 2010, the Company and PST entered into a fifth amendment to the OsseoScrew License Agreement. The fifth amendment includes (i) a milestone payment of a $1.5 million and the issuance of $1.0 million in shares of the Company’s common stock upon market launch in Europe; and (ii) royalty payments based on net sales of licensed products with minimum annual royalties beginning at the end of 2011. During the fourth quarter of 2010, the Company recorded an intangible asset of $2.5 million for a milestone payment required upon market launch in Europe which consisted of the cash payment of $1.5 million and $1.0 million in shares of the Company’s common stock. The Company is amortizing this asset over seven years, the estimated life of the product. The total number of shares of common stock which were issued on December 15, 2010, was 452,488.
	On December 12, 2013, the Company and PST entered into a sixth amendment to the OsseoScrew License Agreement. The sixth amendment provides (i) the royalty rate paid by the Company for net sales of licensed products is increased; (ii) the territory is amended so that the United States is removed from the territory in which the Company can sell and market licensed products, and such rights are non-exclusive in Russia and the People’s Republic of China; (iii)  all milestone payments based on the achievement of certain sales milestones are deleted; and (iv) a $0.3 million milestone payment to be paid upon the achievement of regulatory approval of a licensed product in the People’s Republic of China was added. In connection with this amendment, the Company reversed the $0.6 million accrual it had recorded for the sales milestone payment into cost of goods sold for the year ended December 31, 2013.
	License Agreement with Helix Point, LLC
	In February 2009, the Company entered into a license agreement (the “Helifuse/Helifix License Agreement”) with Helix Point, LLC (“Helix Point”) that provides the Company with a worldwide exclusive license (excluding the People’s Republic of China) to develop and commercialize Helix Point’s proprietary intellectual property related to a device for the treatment of spinal stenosis. The financial terms of the Helifuse/Helifix License Agreement include: (i) a cash payment of $0.2 million payable following the execution of the Helifuse/Helifix License Agreement; (ii) the issuance of $0.4 million of shares of the Company’s common stock following the execution of the Helifuse/Helifix License Agreement; (iii) development and sales milestone payments in cash and the Company’s common stock; and (iv) a royalty payment based on net sales of licensed products, with minimum annual royalties beginning in the year after the first commercial sale of a licensed product. During the third quarter of 2010, the Company recorded an intangible asset of $0.2 million for the assets received as this product is cleared for sale in Europe and technological feasibility is considered to have been achieved. The Company is amortizing this asset over seven years, the estimated life of the product.
	License Agreement with International Spinal Innovations, LLC
	In June 2009, the Company entered into a cross license agreement (the “ISI License Agreement”) with International Spinal Innovations, LLC (“ISI”) that provides the Company with a worldwide license to develop and commercialize ISI’s proprietary intellectual property related to a stand-alone anterior lumbar interbody fusion device. The financial terms of the ISI License Agreement include: (i) the issuance of 260,000 shares of the Company’s common stock following the execution of the ISI License Agreement; (ii) sales milestone payments in cash that could begin to be achieved and paid in 2016; and (iii) a royalty payment based on net sales of licensed products. In 2012, the Company entered into an amended agreement that established a minimum royalty payment amount that began in 2012.
	Distribution Agreement with Parcell Spine, LLC
	In January 2010, the Company entered into an exclusive distribution agreement (the “Parcell Agreement”) with Parcell Spine, LLC (“Parcell Spine”), which provides the Company with the exclusive right to distribute Parcell Spine’s proprietary adult stem cells for the treatment of spinal disorders under either Parcell’s trademarks or Alphatec Spine’s private label. The financial terms of the Parcell Agreement include: (i) a cash payment of $0.5 million payable following the execution of the Parcell Agreement; (ii) a milestone payment consisting of $1.0 million in cash and the issuance of $1.0 million of shares of the Company’s common stock following the successful completion of a pre-clinical study; and (iii) sales milestone payments in cash and the Company’s common stock. During the first quarter of 2010, the Company recorded an IPR&D charge of $0.5 million for the initial cash payment. During the third quarter of 2010, the pre-clinical study milestone was achieved and the Company recorded an IPR&D charge totaling $2.0 million, which consisted of a cash payment of $1.0 million and the issuance of $1.0 million worth of the Company’s common stock. The amounts were expensed as the technological feasibility associated with the IPR&D had not been established since the final prototype of the device had not been completed, additional items subject to risk of completion were necessary to comply with regulatory requirements and no alternative future use exists. The total number of shares of common stock, which were issued in accordance with the agreement for the achievement of a development milestone, was 465,116. In addition, during the third quarter of 2010, the Company recorded an intangible asset of $1.5 million for a milestone payment required upon market launch when the product became commercially ready for sale which consisted of a cash payment of $0.5 million and $1.0 million worth of the Company’s common stock. The Company is amortizing this asset over seven years, the estimated life of the product. The total number of shares of common stock, which were issued in accordance with the agreement for the achievement of a development milestone in September 2010, was 476,190.
	During the year ended December 31, 2013, the Company decided that it would not continue to sell its PureGen product, which is currently the only product commercialized by the Company under the Parcell Agreement. During the year ended December 31, 2013, the Company expensed $0.9 million as impairment charges in cost of goods for the write-off of intangible assets related to the Parcell Agreement and expensed $2.6 million related to the write-off of inventory and certain prepaid assets in cost of goods sold.
	License Agreement with R Tree Innovations LLC
	In September 2010, the Company entered into a License Agreement (the “R Tree License Agreement”) with R Tree Innovations LLC (“R Tree”) that provides the Company with a worldwide license to develop and commercialize R Tree’s proprietary intellectual property related to its Epicage interbody fusion device and related instrumentation. The financial terms of the R Tree License Agreement include: (i) a cash payment of $0.8 million and the issuance of $0.5 million of the Company’s common stock following the execution of the R Tree License Agreement; (ii) development and sales milestone payments in cash that could begin to be achieved and paid in 2013; and (iii) a royalty payment based on net sales of licensed products. During the third quarter of 2010, the Company recorded an intangible asset of $1.3 million following the execution of the R Tree License Agreement. In November 2012, the Company and R Tree entered into an amendment to the R Tree License Agreement (the “R Tree Amendment”). In connection with the R Tree Amendment, the Company made a cash payment of $0.3 million and issued $0.2 million of its common stock to R Tree. The total consideration of $0.5 million was recorded as an intangible asset. The Company is amortizing the intangible asset over seven years, the estimated life of the product. The total number of shares of common stock, which were issued in accordance with the R Tree License Agreement and the R Tree Amendment was 367,044. In October 2013, another milestone was reached and the Company made a $0.3 million cash payment and issued $0.2 million worth of its common stock to R Tree. The total consideration of $0.5 million was recorded as an intangible asset.
	Cervical Interbody Spacer Supply Agreement
	In October 2012, the Company entered into a supply agreement with a third party supplier whereby the Company acquired exclusive worldwide distribution rights to sell an anchored, fully retractable cervical inter-body spacer (the “Cervical Spacer Supply Agreement”). The Company was required to make up-front payments totaling $1.0 million upon the execution of the Cervical Spacer Supply Agreement. The $1.0 million up-front payments were capitalized as an intangible asset and is being amortized over the 7-year term of the Cervical Spacer Supply Agreement. Additionally, the Company was required to meet certain minimum purchase requirements of up to $5.9 million per year to maintain its exclusive distribution rights. In September 2014, the Company entered into an amendment to the Cervical Spacer Supply Agreement that eliminated the minimum purchase requirements and modified the distribution rights to non-exclusive.
	Asset Purchase Agreement
	In July 2014, the Company entered into an asset purchase and product development services agreement (the "Asset Agreement") whereby the Company purchased rights to the conceptual design for an intervertebral implant device. The financial terms of the Agreement include payments in cash and the Company's common stock upon achievement of various milestones. The Company accounted for this arrangement as an asset acquisition. In the year ended December 31, 2014, the Company made cash payments totaling $0.2 million and issued 72,992 shares of the Company's common stock valued at $0.1 million. The Company recognized the cash and stock payments of $0.3 million as in-process research and development expense in the year ended December 31, 2014.

Debt

Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt	Debt
	MidCap Loan and Security Agreement
	On August 30, 2013, the Company entered into the Amended Credit Facility with MidCap. The Amended Credit Facility amended and restated the prior credit facility that the Company had with MidCap (the "Prior Credit Facility").
	Pursuant to the Amended Credit Facility, the Company increased the borrowing limit from $50 million to $73 million. The Company also extended the maturity to August 2016. The Amended Credit Facility consists of a $33 million term loan, $28 million of which was drawn at closing and the remaining $5 million of which was drawn in April 2014, and a revolving line of credit with a maximum borrowing base of $40 million, of which $31.8 million was outstanding at December 31, 2014. The Company used the term loan proceeds of $28 million drawn at closing to repay a portion of the outstanding balance on the prior revolving line of credit.
	The term loan interest rate is priced at the London Interbank Offered Rate ("LIBOR") plus 8.0%, subject to a 9.5% floor, and the revolving line of credit interest rate bears interest at LIBOR plus 6.0%, reset monthly. At December 31, 2014, the revolving line of credit carries an interest rate of 6.2% and the term loan carries an interest rate of 9.5%. The borrowing base is determined, from time to time, based on the value of domestic eligible accounts receivable and domestic eligible inventory. As collateral for the Amended Credit Facility, the Company granted MidCap a security interest in substantially all of its assets, including all accounts receivable and all securities evidencing its interests in its subsidiaries. In addition to monthly payments of interest, monthly repayments of $0.3 million of the principal for the term loan were made beginning in October 2013, increasing to $0.5 million beginning in October 2014, and are due through maturity, with the remaining principal due upon maturity.
	In connection with the execution of the Amended Credit Facility, the Company incurred approximately $0.4 million in costs, which were capitalized as debt issuance costs within the consolidated balance sheet as of December 31, 2014. At December 31, 2014, $0.4 million remains as unamortized debt issuance costs related to the prior and Amended Credit Facility within the consolidated balance sheet, which will be amortized over the remaining term of the Amended Credit Facility.
	On June 7, 2012, the Company entered into the Prior Credit Facility with MidCap, which permitted the Company to borrow up to $40 million under a revolving line of credit and included an option to increase the borrowing base to $50 million with the prior consent of MidCap. As collateral for the Prior Credit Facility, the Company granted MidCap a security interest in substantially all of its assets, including all accounts receivable and all securities evidencing its interests in its subsidiaries.
	Upon execution of the Prior Credit Facility, the Company drew $34.3 million on the Credit Facility to pay off its existing term loan with Silicon Valley Bank (“SVB”) totaling $8.1 million and its existing line of credit with SVB totaling $17.6 million (collectively the “SVB Credit Facility”). The Company paid early termination and other fees to SVB associated with the SVB Credit Facility of $2.3 million and wrote-off $0.6 million of unamortized debt issuance and debt discount costs related to the SVB Credit Facility. The total loss on extinguishment of debt costs of $2.9 million is included in interest expense in the year ended December 31, 2012. The Company paid an up-front commitment fee to MidCap of $0.2 million and debt issuance costs of $0.2 million, which were capitalized as deferred debt issuance costs.
	The Amended Credit Facility includes traditional lending and reporting covenants including a fixed charge coverage ratio, a senior leverage ratio and a total leverage ratio to be maintained by the Company. The Amended Credit Facility also provides for several potential events of default, such as payment default and insolvency conditions, which could cause interest to be charged at a rate which is up to five percentage points above the rate effective immediately before the event of default or result in MidCap’s right to declare all outstanding obligations immediately due and payable.
	In January 2013, the Company entered into a limited waiver and limited consent agreement with MidCap (the “Waiver”). Under the Waiver, MidCap waived certain provisions of the Prior Credit Facility in connection with the acquisition of the assets of Phygen, LLC ("Phygen") and related to the maintenance of cash balances in the U.S. In February 2013, the Company and MidCap entered into a first amendment to the Prior Credit Facility (the "First Amendment to the Credit Facility”). The First Amendment to the Credit Facility allowed the Company to exclude payments related to the Phygen acquisition and the settlement agreement with Cross Medical Products, LLC (“Cross”) from calculation of the fixed charge coverage ratio and the senior leverage ratio. In conjunction with the First Amendment to the Credit Facility, the Company paid MidCap a fee of $0.1 million. In July 2013, the Company entered into a second limited waiver and limited consent agreement with MidCap (the “Second Waiver”). Under the Second Waiver, MidCap waived certain provisions of the Prior Credit Facility related to the maintenance of cash balances in the U.S. for past periods through September 30, 2013. On August 30, 2013, the Company entered into the Amended Credit Agreement with MidCap.
	On March 17, 2014, the Company entered into a first amendment to the Amended Credit Facility with MidCap (the "First Amendment to the Amended Credit Facility"). Under the First Amendment to the Amended Credit Facility, MidCap gave the Company its consent to enter into the Facility Agreement (defined below) and make settlement payments in connection with the Orthotec litigation. The First Amendment to the Amended Credit Facility also added a total leverage ratio financial covenant. The Company was in compliance with all of the covenants of the Amended Credit Facility as of December 31, 2014.
	During the year ended December 31, 2014, the Company repaid $156.1 million and drew an additional $163.1 million on its working capital line of credit under the Amended Credit Facility. The balance of the line of credit and the term loan as of December 31, 2014 was $31.8 million and $28.6 million, respectively. Amortization of the debt discount and debt issuance costs, accretion of the finance charge and non-cash extinguishment of debt costs, which were recorded as non-cash interest expense, totaled $0.3 million, $0.2 million and $0.9 million for the years ended December 31, 2014, 2013 and 2012, respectively. Interest expense for the term loans and the Company’s working capital line of credit, excluding debt discount and debt issuance cost amortization, accretion of the additional finance charge and extinguishment of debt costs, totaled $5.3 million, $3.6 million and $2.6 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	Deerfield Facility Agreement
	On March 17, 2014, the Company entered into a facility agreement (the “Facility Agreement”) with Deerfield, pursuant to which Deerfield agreed to loan the Company up to $50 million, subject to the terms and conditions set forth in the Facility Agreement. Under the terms of the Facility Agreement, the Company had the option, but was not required, upon certain conditions to draw the entire amount available under the Facility Agreement, at any time until January 30, 2015 (the “Draw Period”), provided that the initial draw be used for a portion of the payments made in connection with the Orthotec settlement described in Note 7 below. Following such initial draw down, the Company was permitted to draw down additional amounts under the Facility Agreement up to an aggregate $15 million for working capital or general corporate purposes in $2.5 million increments until the end of the Draw Period. The Company agreed to pay Deerfield, upon each disbursement of funds under the Facility Agreement, a transaction fee equal to 2.5% of the principal amount of the funds disbursed. Amounts borrowed under the Facility Agreement bear interest at a rate of 8.75% per annum and are payable on the third, fourth and fifth anniversary date of the first amount borrowed under the Facility Agreement, with the final payment due on March 20, 2019.
	The Facility Agreement also contains various representations and warranties, and affirmative and negative covenants, customary for financings of this type, including restrictions on the ability of the Company and its subsidiaries to incur additional indebtedness or liens on its assets, except as permitted under the Facility Agreement. As security for our repayment of our obligations under the Facility Agreement, the Company granted to Deerfield a security interest in substantially all of our property and interests in property, which is subordinated to the security interest granted under the Amended Credit Facility.
	In connection with the execution of the Facility Agreement on March 17, 2014, the Company issued to Deerfield warrants to purchase an aggregate of 6,250,000 shares of the Company’s common stock (the “Initial Warrants”) (See Note 9). Additionally, the Company agreed that upon each disbursement under the Facility Agreement, the Company would issue to Deerfield warrants to purchase up to 10,000,000 shares of the Company’s common stock, in proportion to the amount of draw compared to the total $50 million facility (the "Draw Warrants") (See Note 9).
	On March 20, 2014, the Company made an initial draw of $20 million under the Facility Agreement and received net proceeds of $19.5 million to fund the portion of the Orthotec settlement payment obligations that were due in 2014. The $0.5 million transaction fee was recorded as a debt discount and is being amortized over the term of the draw, which ends March 20, 2019. In connection with this borrowing, the Company issued Draw Warrants to purchase 4,000,000 shares of common stock, which were valued at $4.7 million and recorded as a debt discount and is being amortized over the term of the draw. Additionally, $2.3 million of the value of the Initial Warrants was reclassified as a debt discount and is being amortized through interest expense over the term of the debt using the effective interest method.
	On November 21, 2014, the Company made a second draw of $6 million under the Facility Agreement and received net proceeds of $5.9 million to fund the portion of the Orthotec settlement payments through 2016. The $0.2 million transaction fee was recorded as a debt discount and is being amortized over the remaining term of the draw, which ends March 20, 2019. In connection with this borrowing, the Company issued Draw Warrants to purchase 1,200,000 share of common stock, which were valued at $0.9 million and recorded as a debt discount and is being amortized over the term of the debt using the effective interest method.
	Orthotec settlement payments of $18.6 million were made in the year ended December 31, 2014, leaving remaining proceeds of $4.4 million, which are classified as short-term restricted cash and $2.4 million, which are classified as long-term restricted cash under other assets borrowed under the Facility Agreement, as their use is limited under the terms of the Facility Agreement for the payments of amounts due under the Orthotec litigation settlement agreement. The amounts borrowed under the Facility Agreement, which total $26.5 million in principal and accrued interest as of December 31, 2014, are due in three equal annual payments beginning March 20, 2017. Additionally, $0.2 million of the value of the Initial Warrants was reclassified as a debt discount and is being amortized through interest expense over the term of the debt using the effective interest method.
	Other Debt Agreements
	The Company has various capital lease arrangements. The leases bear interest at rates ranging from 6.6% to 9.6%, are generally due in monthly principal and interest installments, are collateralized by the related equipment, and have various maturity dates through October 2017.
	Long-term debt consists of the following (in thousands):
		December 31,
		2014			2013
	Amended Credit Facility with MidCap	$	60,390		$	52,081
	Facility Agreement with Deerfield	26,000			—
	Note payable related to software license purchases	250			58
	Financing agreements for premiums on insurance policies	1,580			1,427
	Total	88,220			53,566
	Add: capital leases (See Note 7)	1,784			1,336
	Less: debt discount	(7,331		)	—
	Total	82,673			54,902
	Less: current portion of long-term debt	(8,076		)	(4,924		)
	Total long-term debt, net of current portion	$	74,597		$	49,978
	Principal payments on debt are as follows as of December 31, 2014 (in thousands):
	Year Ending December 31,
	2015	$	7,346
	2016	54,874
	2017	8,667
	2018	8,667
	2019	8,666
	Thereafter	—
	Total	88,220
	Add: capital lease principal payments	1,784
	Less: debt discount	(7,331		)
	Total	82,673
	Less: current portion of long-term debt	(8,076		)
	Long-term debt, net of current portion	$	74,597

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Leases
	During the first quarter of 2008, the Company entered into a lease agreement and sublease agreement in order to consolidate the use and occupation of its then existing premises into two adjacent facilities, as described below. The Company also leases certain equipment and vehicles under operating leases which expire on various dates through 2018, and certain equipment under capital leases which expire on various dates through 2017.
	In February 2008, the Company entered into a sublease agreement (the “Sublease”), for office, engineering, and research and development space. The Sublease term commenced May 2008 and ends on January 31, 2016.
	The Company is obligated under the Sublease to pay base rent and certain operating costs and taxes for the building. Monthly base rent payable by the Company was approximately $80,500 during the first year of the Sublease, increasing annually at a fixed annual rate of 2.5% to approximately $93,500 per month in the final year of the Sublease. The Company’s rent was abated for months one through seven of the Sublease. At the sublease inception, the Company paid a security deposit in the amount of approximately $93,500.
	In March 2008, the Company entered into a lease agreement (the “Lease”) for additional office, engineering, research and development and warehouse and distribution space. The Lease term commenced on December 1, 2008 and ends on January 31, 2017. The Company is obligated under the Lease to pay base rent and certain operating costs and taxes for the building. The monthly base rent payable by the Company was approximately $73,500 during the first year of the Lease, increasing annually at a fixed annual rate of 3.0% to approximately $93,000 per month in the final year of the Lease. The Company’s rent was abated for the months two through eight of the term of the Lease in the amount of $38,480. At the lease inception, the Company paid a security deposit in the amount of approximately $293,200 consisting of cash and two letters of credit. In the event the Company achieves certain financial milestones, the lessor is obligated to return a portion of the security deposit to the Company. The lessor provided a tenant improvement allowance of $1.1 million to assist with the configuration of the facility to meet the Company’s business needs.
	Future minimum annual lease payments under the Company’s operating and capital leases are as follows (in thousands):
	Year ending December 31,	Operating		Capital
	2015	$	3,150	$	846
	2016	1,829		787
	2017	377		347
	2018	73		—
	2019	8		—
	Thereafter	—		—
		$	5,437	1,980
	Less: amount representing interest			(196		)
	Present value of minimum lease payments			1,784
	Current portion of capital leases			(730		)
	Capital leases, less current portion			$	1,054
	Rent expense under operating leases for the years ended December 31, 2014, 2013 and 2012 was $3.4 million, $3.8 million and $3.7 million, respectively.
	Litigation
	On March 15, 2014, the Company, Orthotec, LLC and certain other parties, including certain directors and affiliate of the Company, entered into a binding term sheet (the "Binding Term Sheet") to resolve the Orthotec, LLC v. Surgiview, S.A.S, et al. matter in the Superior Court of California, Los Angeles County and related litigation matters (the "Orthotec Settlement"). Pursuant to the terms contained in the Binding Term Sheet, the Company agreed to pay Orthotec, LLC $49 million in cash, including initial cash payments totaling $1.75 million, which the Company previously paid in March 2014, and an additional lump sum payment of $15.75 million, which the Company previously paid in April 2014. The Company agreed to pay the remaining $31.5 million in 28 quarterly installments of $1.1 million and then one additional quarterly installment of $700,000, commencing October 1, 2014. The Company made the first quarterly installment payment of $1.1 million, which was paid on October 1, 2014. The Company has the right to prepay the amounts due without penalty. In addition, the unpaid balance of the amounts due will accrue interest at the rate of 7 percent per year beginning May 15, 2014 until the amounts due are paid in full. The accrued but unpaid interest will be paid in quarterly installments of $1.1 million (or the full amount of the accrued but unpaid interest if less than $1.1 million) following the full payment of the $31.5 million in quarterly installments described above. No interest will accrue on the accrued interest. The Binding Term Sheet provided for mutual releases of all claims in the Orthotec, LLC v. Surgiview, S.A.S, et al. matter in the Superior Court of California, Los Angeles County and all other related litigation matters involving the Company and its directors and affiliates.
	On September 26, 2014, the Company entered into a Settlement and Release Agreement, dated as of August 13, 2014, by and among the Company and its direct subsidiaries, including Alphatec Spine, Inc., Alphatec Holdings International C.V., Scient'x S.A.S. and Surgiview S.A.S.; HealthpointCapital, LLC, HealthpointCapital Partners, L.P., HealthpointCapital Partners II, L.P., John H. Foster and Mortimer Berkowitz III; and Orthotec, LLC and Patrick Bertranou, (the "Settlement Agreement"). The Settlement Agreement contains substantially the same business terms as the Binding Term Sheet set forth above, and supersedes the Binding Term Sheet.
	On August 10, 2010, a purported securities class action complaint was filed in the United States District Court for the Southern District of California on behalf of all persons who purchased the Company's common stock between December 19, 2009 and August 5, 2010 against the Company and certain of its directors and officers alleging violations of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b-5 promulgated thereunder. On February 17, 2011, an amended complaint was filed against the Company and certain of its directors and officers adding alleged violations of the Securities Act of 1933 (the "Securities Act"), as amended. HealthpointCapital, Jefferies & Company, Inc., Canaccord Adams, Inc., Cowen and Company, Inc., and Lazard Capital Markets LLC are also defendants in this action. The complaint alleges that the defendants made false or misleading statements and failed to disclose material facts about the Company’s business, financial condition, operations and prospects, particularly relating to the Scient’x transaction and the Company's financial guidance following the closing of the acquisition. The complaint seeks unspecified monetary damages, attorneys’ fees, and other unspecified relief. The Company filed a motion to dismiss the amended complaint on April 18, 2011. The district court granted the motion to dismiss with leave to amend on March 22, 2012. On April 19, 2012, the lead plaintiff filed a Second Amended Complaint alleging violations of Sections 10(b) and 20(a) of the Exchange Act and violations of Section 11, 12(a)(2), and 15 of the Securities Act against the same named defendants. On May 3, 2012, the Company filed a motion to dismiss the Second Amended Complaint. The district court granted that motion without leave to amend and entered final judgment in the Company’s favor on March 28, 2013. On April 17, 2013, the lead plaintiff filed a notice of appeal to the United States Court of Appeals for the Ninth Circuit. The appeal has been fully briefed. The Company believes that the claims are without merit and it intends to vigorously defend itself against this complaint. However, the outcome of the litigation cannot be predicted at this time and any outcome that is adverse to the Company, regardless of who the defendant is, could have a significant adverse effect on its financial condition and results of operations.
	On August 25, 2010, an alleged shareholder of the Company filed a derivative lawsuit in the Superior Court of California, San Diego County, purporting to assert claims on behalf of the Company against all of its directors and certain of its officers and HealthpointCapital. Following the filing of this complaint, similar complaints were filed in the same court and in the U.S. District Court for the Southern District of California against the same defendants containing similar allegations. The complaint filed in federal court was dismissed by the plaintiff without prejudice in July 2011. The state court complaints were consolidated into a single action and the Company was named as a nominal defendant in the consolidated action. Each complaint alleges that the Company’s directors and certain of its officers breached their fiduciary duties to the Company related to the Scient’x transaction, and allegedly made false statements that led to unjust enrichment of HealthpointCapital and certain of the Company’s directors. The complaints seek unspecified monetary damages and an order directing the Company to adopt certain measures purportedly designed to improve its corporate governance and internal procedures. On January 8, 2014, the parties reached an agreement in principle to resolve all claims in exchange for corporate governance reforms and payment of attorneys’ fees in the amount of $5.25 million, to be paid by the Company’s and HeathpointCapital’s respective insurance carriers. The final settlement was approved by the Court in August 2014.
	At December 31, 2014, the probable outcome of any of the aforementioned litigation matters that have not reached a settlement cannot be determined nor can the Company estimate a range of potential loss. Accordingly, in accordance with the authoritative guidance on the evaluation of contingencies, the Company has not recorded an accrual related to any litigation matters that have not reached a settlement. The Company is and may become involved in various other legal proceedings arising from its business activities. While management does not believe the ultimate disposition of the above matters that have not yet been settled will have a material adverse impact on the Company’s consolidated results of operations, cash flows or financial position, litigation is inherently unpredictable, and depending on the nature and timing of these proceedings, an unfavorable resolution could materially affect the Company’s future consolidated results of operations, cash flows or financial position in a particular period.
	Royalties
	The Company has entered into various intellectual property agreements requiring the payment of royalties based on the sale of products that utilize such intellectual property. These royalties primarily relate to products sold by Alphatec Spine and are calculated either as a percentage of net sales or in one instance on a per-unit sold basis. Royalties are included on the accompanying consolidated statement of operations as a component of cost of revenues.

Redeemable_Preferred_Stock_and

Redeemable Preferred Stock and Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Redeemable Preferred Stock and Stockholders' Equity	Redeemable Preferred Stock and Stockholders’ Equity
	Redeemable Preferred Stock
	The Company issued shares of redeemable preferred stock in connection with its initial public offering in June 2006. As of December 31, 2014, the redeemable preferred stock carrying value was $23.6 million and there were 20 million shares of redeemable preferred stock authorized. The redeemable preferred stock is not convertible into common stock but is redeemable at $9.00 per share, (i) upon the Company’s liquidation, dissolution or winding up, or the occurrence of certain mergers, consolidations or sales of all or substantially all of the Company’s assets, before any payment to the holders of the Company’s common stock, or (ii) at the Company’s option at any time. Holders of redeemable preferred stock are generally not entitled to vote on matters submitted to the stockholders, except with respect to certain matters that will affect them adversely as class, and are not entitled to receive dividends. The carrying value of the redeemable preferred stock was $7.11 per share at December 31, 2014 and 2013.
	The redeemable preferred stock is required to be shown in the Company’s financial statements separate from stockholders’ equity and any adjustments to its carrying value to its redemption value up to its redemption value of $9.00 per share will be reported as a dividend.
	Eclipse Advisors, LLC
	On May 8, 2012, the Company entered into an equity line of credit arrangement with Eclipse Advisors, LLC (“Eclipse”), which provides that, upon the terms and subject to the conditions set forth therein, the Company is entitled to sell and Eclipse is committed to purchase up to $25 million of shares of the Company’s common stock over a 24-month term, which expired on May 8, 2014 (the “Investment Agreement). From time to time, and at the Company’s sole discretion, the Company may present Eclipse with put notices, to purchase the Company’s common stock in two tranches over a 31-day period (a “put period”) with each put period subject to being reduced by the Company based on a minimum threshold price of the Company’s common stock during the put period. The Company may not present Eclipse with a new put notice at any time there is an outstanding put notice.
	Once presented with a put notice, Eclipse is required to purchase: (i) 50% of the dollar amount of the shares specified in the put notice on the 16th day after the date of the put notice; and (ii) 50% of the dollar amount of the shares specified in the put notice on the 31st day after the date of the put notice. The price per share for the sale of such common stock for each of the two closings in a put period shall be 90% of the volume weighted average price for the Company’s common stock over the trading days that exist during the 15 days prior to such closing date. If the daily volume weighted average price of the Company’s common stock falls below a threshold price established by the Company on any trading day during a put period, the Company has the right to send a cancellation notice to Eclipse, which will reduce the Company’s obligation to sell the shares to Eclipse to no greater than 50% of the dollar amount set forth in the put notice.
	Upon execution of the Investment Agreement and as provided for therein, the Company issued Eclipse 231,045 shares of common stock representing a $500,000 commitment fee, determined by dividing $500,000 by the volume weighted average price for the Company’s common stock for the five trading days preceding the effective date of the Investment Agreement. The Company has not sold any shares to Eclipse under the Investment Agreement.
	9. Equity Transactions
	Warrants
	In connection with the execution of the Facility Agreement, on March 17, 2014, the Company issued to Deerfield the Initial Warrants to purchase an aggregate of 6,250,000 shares of the Company’s common stock immediately exercisable at an exercise price equal to $1.39 expiring on March 17, 2020. The number of shares of common stock into which the Initial Warrants are exercisable and the exercise price will be adjusted to reflect any stock splits, payment of stock dividends, recapitalizations, reclassifications or other similar adjustments in the number of outstanding shares of the Company’s common stock. The warrants have the same dividend rights to the same extent as if the warrants had been exercised for shares of common stock.
	The Company agreed that upon each disbursement borrowing under the Facility Agreement, the Company would issue to Deerfield Draw Warrants to purchase up to an aggregate of 10,000,000 shares of the Company’s common stock, at an exercise price equal to the lesser of the Initial Warrant exercise price or the average daily volume weighted average price per share of the Company’s common stock for the 15 days following the request for borrowing. The number of Draw Warrants issued for each draw will be in proportion to the amount of draw compared to the total $50 million facility.
	The Initial Warrants were valued on March 17, 2014 using a Black-Scholes option pricing model that resulted in a value of $5.7 million, which was recorded as a current liability with an offset to a deferred charge asset and will be amortized on a straight line basis through interest expense over the term of the Facility Agreement commitment period ended January 30, 2015. To the extent the Company draws on the $50 million Facility Agreement, a proportionate amount of the unamortized current deferred charge will be reclassified as debt discount and amortized through interest expense over the term of the debt using the effective interest method.
	On March 20, 2014, the Company made an initial draw of $20 million under the Facility Agreement and received net proceeds of $19.5 million to fund the portion of the Orthotec settlement payment obligations that were due in 2014. In connection with this borrowing, the Company issued Draw Warrants to purchase 4,000,000 shares of common stock at an exercise price of $1.39. The Draw Warrants were valued at $4.7 million using the Black-Scholes option pricing model, which was recorded as a current liability with an offset to debt discount.
	On November 21, 2014, the Company made a second draw of $6 million under the Facility Agreement and received net proceeds of $5.9 million to fund the portion of the Orthotec settlement payments payable through 2016. The $0.2 million transaction fee was recorded as a debt discount and is being amortized over the remaining term of the draw, which ends March 20, 2019. In connection with this borrowing, the Company issued Draw Warrants to purchase 1,200,000 shares of common stock at an exercise price of $1.39, which were valued at $0.9 million and recorded as a debt discount and is being amortized over the term of the draw.
	As of December 31, 2014, the outstanding Initial Warrants and Draw Warrants to purchase an aggregate of 11,450,000 shares of common stock outstanding were revalued to their fair value with a gain recorded to to other income (expense) of $2.6 million for the year ended December 31, 2014. The warrant liability of $8.7 million is recorded as common stock warrant liabilities within current liabilities on the condensed consolidated balance sheet as of December 31, 2014.
	At December 31, 2014, the Company's outstanding warrants were valued using the Black-Scholes option pricing model. This is a Level 3 measurement using the following assumptions:
		December 31, 2014
	Risk-free interest rate	1.8	%
	Dividend yield	—	%
	Expected volatility	61	%
	Expected life (years)	5.3

Equity_Transactions_Equity_Tra

Equity Transactions Equity Transactions	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Equity Transactions	Redeemable Preferred Stock and Stockholders’ Equity
	Redeemable Preferred Stock
	The Company issued shares of redeemable preferred stock in connection with its initial public offering in June 2006. As of December 31, 2014, the redeemable preferred stock carrying value was $23.6 million and there were 20 million shares of redeemable preferred stock authorized. The redeemable preferred stock is not convertible into common stock but is redeemable at $9.00 per share, (i) upon the Company’s liquidation, dissolution or winding up, or the occurrence of certain mergers, consolidations or sales of all or substantially all of the Company’s assets, before any payment to the holders of the Company’s common stock, or (ii) at the Company’s option at any time. Holders of redeemable preferred stock are generally not entitled to vote on matters submitted to the stockholders, except with respect to certain matters that will affect them adversely as class, and are not entitled to receive dividends. The carrying value of the redeemable preferred stock was $7.11 per share at December 31, 2014 and 2013.
	The redeemable preferred stock is required to be shown in the Company’s financial statements separate from stockholders’ equity and any adjustments to its carrying value to its redemption value up to its redemption value of $9.00 per share will be reported as a dividend.
	Eclipse Advisors, LLC
	On May 8, 2012, the Company entered into an equity line of credit arrangement with Eclipse Advisors, LLC (“Eclipse”), which provides that, upon the terms and subject to the conditions set forth therein, the Company is entitled to sell and Eclipse is committed to purchase up to $25 million of shares of the Company’s common stock over a 24-month term, which expired on May 8, 2014 (the “Investment Agreement). From time to time, and at the Company’s sole discretion, the Company may present Eclipse with put notices, to purchase the Company’s common stock in two tranches over a 31-day period (a “put period”) with each put period subject to being reduced by the Company based on a minimum threshold price of the Company’s common stock during the put period. The Company may not present Eclipse with a new put notice at any time there is an outstanding put notice.
	Once presented with a put notice, Eclipse is required to purchase: (i) 50% of the dollar amount of the shares specified in the put notice on the 16th day after the date of the put notice; and (ii) 50% of the dollar amount of the shares specified in the put notice on the 31st day after the date of the put notice. The price per share for the sale of such common stock for each of the two closings in a put period shall be 90% of the volume weighted average price for the Company’s common stock over the trading days that exist during the 15 days prior to such closing date. If the daily volume weighted average price of the Company’s common stock falls below a threshold price established by the Company on any trading day during a put period, the Company has the right to send a cancellation notice to Eclipse, which will reduce the Company’s obligation to sell the shares to Eclipse to no greater than 50% of the dollar amount set forth in the put notice.
	Upon execution of the Investment Agreement and as provided for therein, the Company issued Eclipse 231,045 shares of common stock representing a $500,000 commitment fee, determined by dividing $500,000 by the volume weighted average price for the Company’s common stock for the five trading days preceding the effective date of the Investment Agreement. The Company has not sold any shares to Eclipse under the Investment Agreement.
	9. Equity Transactions
	Warrants
	In connection with the execution of the Facility Agreement, on March 17, 2014, the Company issued to Deerfield the Initial Warrants to purchase an aggregate of 6,250,000 shares of the Company’s common stock immediately exercisable at an exercise price equal to $1.39 expiring on March 17, 2020. The number of shares of common stock into which the Initial Warrants are exercisable and the exercise price will be adjusted to reflect any stock splits, payment of stock dividends, recapitalizations, reclassifications or other similar adjustments in the number of outstanding shares of the Company’s common stock. The warrants have the same dividend rights to the same extent as if the warrants had been exercised for shares of common stock.
	The Company agreed that upon each disbursement borrowing under the Facility Agreement, the Company would issue to Deerfield Draw Warrants to purchase up to an aggregate of 10,000,000 shares of the Company’s common stock, at an exercise price equal to the lesser of the Initial Warrant exercise price or the average daily volume weighted average price per share of the Company’s common stock for the 15 days following the request for borrowing. The number of Draw Warrants issued for each draw will be in proportion to the amount of draw compared to the total $50 million facility.
	The Initial Warrants were valued on March 17, 2014 using a Black-Scholes option pricing model that resulted in a value of $5.7 million, which was recorded as a current liability with an offset to a deferred charge asset and will be amortized on a straight line basis through interest expense over the term of the Facility Agreement commitment period ended January 30, 2015. To the extent the Company draws on the $50 million Facility Agreement, a proportionate amount of the unamortized current deferred charge will be reclassified as debt discount and amortized through interest expense over the term of the debt using the effective interest method.
	On March 20, 2014, the Company made an initial draw of $20 million under the Facility Agreement and received net proceeds of $19.5 million to fund the portion of the Orthotec settlement payment obligations that were due in 2014. In connection with this borrowing, the Company issued Draw Warrants to purchase 4,000,000 shares of common stock at an exercise price of $1.39. The Draw Warrants were valued at $4.7 million using the Black-Scholes option pricing model, which was recorded as a current liability with an offset to debt discount.
	On November 21, 2014, the Company made a second draw of $6 million under the Facility Agreement and received net proceeds of $5.9 million to fund the portion of the Orthotec settlement payments payable through 2016. The $0.2 million transaction fee was recorded as a debt discount and is being amortized over the remaining term of the draw, which ends March 20, 2019. In connection with this borrowing, the Company issued Draw Warrants to purchase 1,200,000 shares of common stock at an exercise price of $1.39, which were valued at $0.9 million and recorded as a debt discount and is being amortized over the term of the draw.
	As of December 31, 2014, the outstanding Initial Warrants and Draw Warrants to purchase an aggregate of 11,450,000 shares of common stock outstanding were revalued to their fair value with a gain recorded to to other income (expense) of $2.6 million for the year ended December 31, 2014. The warrant liability of $8.7 million is recorded as common stock warrant liabilities within current liabilities on the condensed consolidated balance sheet as of December 31, 2014.
	At December 31, 2014, the Company's outstanding warrants were valued using the Black-Scholes option pricing model. This is a Level 3 measurement using the following assumptions:
		December 31, 2014
	Risk-free interest rate	1.8	%
	Dividend yield	—	%
	Expected volatility	61	%
	Expected life (years)	5.3

Stock_Benefit_Plans_and_StockB

Stock Benefit Plans and Stock-Based Compensation	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Benefit Plans and Stock-Based Compensation	Stock Benefit Plans and Stock-Based Compensation
	In 2005, the Company adopted its 2005 Employee, Director, and Consultant Stock Plan (the “2005 Plan”). The 2005 Plan allows for the grant of options, restricted stock and restricted stock unit awards to employees, directors, and consultants of the Company. The 2005 Plan has 15,800,000 shares of common stock reserved for issuance. The Board of Directors determines the terms of the restricted stock, the terms of the restricted stock units, and the terms of the stock options, including the number of shares for which each option is granted, the exercise price, vesting schedule, expiration date, and whether restrictions will be imposed on the shares subject to options. Options granted under the 2005 Plan expire no later than 10 years from the date of grant (5 years for incentive stock options granted to holders of more than 10% of the Company’s voting stock). Options generally vest over a four year period and may be immediately exercisable upon a change of control of the Company. The exercise price of incentive stock options may not be less than 100% of the fair value of the Company’s common stock on the date of grant. The exercise price of any option granted to a 10% stockholder may be no less than 110% of the fair value of the Company’s common stock on the date of grant. At December 31, 2014, approximately 3.4 million shares of common stock remained available for issuance under the 2005 Plan.
	On July 30, 2014, the Company amended the 2005 Plan (the “Plan Amendment”) to authorize the granting of time-based and performance-based restricted stock units, which represent a contingent entitlement to receive shares of the Company’s common stock, to employees, directors and consultants of the Company under the Plan. Prior to the Plan Amendment, the Plan provided solely for the granting of stock options and restricted stock.
	Stock Options
	A summary of the Company’s stock option activity under the 2005 Plan and related information is as follows (in thousands, except as indicated and per share data):
		Shares		Weighted		Weighted	Aggregate
				average		average	intrinsic
				exercise		remaining	value
				price		contractual
						term
						(in years)
	Outstanding at December 31, 2013	7,761		$	2.23	7.59	$	753
	Granted	2,019		$	1.42	—	—
	Exercised	(21	)	$	1.33	—	—
	Forfeited	(1,492	)	$	1.99	—	—
	Outstanding at December 31, 2014	8,267		$	2.08	7.35	$	71
	Options vested and exercisable at December 31, 2014	4,149		$	2.46	6.16	$	27
	Options vested and expected to vest at December 31, 2014	7,819		$	2.11	7.26	$	64
	The weighted-average grant-date fair value per share of stock options granted during the years ended December 31, 2014, 2013 and 2012 was $0.81, $1.09 and $1.10, respectively. The aggregate intrinsic value of options at December 31, 2014 is based on the Company’s closing stock price on that date of $1.41 per share.
	As of December 31, 2014, there was $7.5 million of unrecognized compensation expense for stock options and awards which is expected to be recognized on a straight-line basis over a weighted average period of approximately 2.5 years. The total intrinsic value of options exercised was immaterial for the years ended December 31, 2014, 2013 and 2012.
	Restricted Stock Awards
	The following table summarizes information about the restricted stock awards activity (in thousands, except as indicated and per share data):
		Shares		Weighted		Weighted
				average		average
				grant		remaining
				date fair		recognition
				value		period
						(in years)
	Unvested at December 31, 2013	807		$	1.88	2.3
	Awarded	493		$	1.32
	Vested	(155	)	$	2.25
	Forfeited	(455	)	$	1.57
	Unvested at December 31, 2014	690		$	1.6	1.83
	The weighted average fair value per share of awards granted during the years ended December 31, 2014, 2013 and 2012 was $1.32, $1.97 and $1.57, respectively.
	Performance Based Restricted Stock Units
	In July 2014, the Company granted 932,000 performance-based restricted stock units ("PSUs") to certain employees under its 2005 Plan. The PSUs vest based upon the Company's achievement of certain performance goals over the period from July 1, 2014 through December 31, 2016. The number of PSUs that may vest varies between 0%-200% based on the achievement of such goals. The PSUs were valued at $1.42 per share based on the closing price of the Company's common stock on the date of grant. For purposes of measuring compensation expense, the amount of PSUs ultimately expected to vest is estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. The recognition of compensation expense associated with PSUs requires judgment in assessing the probability of meeting the performance goals, as well as defined criteria for assessing achievement of the performance-related goals.
		Shares		Weighted		Weighted
				average		average
				grant		remaining
				date fair		recognition
				value		period
						(in years)
	Unvested at December 31, 2013	—		$	—	0
	Awarded	932		$	1.42
	Vested	—		$	—
	Forfeited	(78	)	$	—
	Unvested at December 31, 2014	854		$	1.42	2
	Warrants
	In March 2012, the Company entered into a consulting agreement with a third-party entity pursuant to which the Company issued a warrant to the consultant to purchase an aggregate of 500,000 shares of the Company’s common stock at an exercise price of $2.50 per share. The warrant expires on March 1, 2015.
	In December 2011, in connection with the third amendment to the SVB Credit Facility, finance charges totaling $0.2 million were waived in exchange for the issuance to SVB of warrants to purchase 93,750 shares of the Company’s common stock. The warrants are immediately exercisable, can be exercised through a cashless exercise, have an exercise price of $1.60 per share and have a ten year term.
	Elite Medical Holdings and Pac 3 Surgical Collaboration Agreement
	In October 2013, the Company entered into a three-year collaboration agreement with a third party to provide consultation services to assist the Company in the development of its products and its products in development. Under the terms of the collaboration agreement, the Company will gain exclusive rights to the use of all intellectual property developed by the collaborators. The Company will make three annual payments to the collaborator as sole consideration for services provided, totaling an aggregate of up to $8 million, paid in common stock of Alphatec Holdings at a per share price of $1.95, which was equal to the average NASDAQ closing price of the common stock on the five days leading up to and including the date of signing the collaboration agreement. The actual number of shares issued each year will be determined by the fair market value of the services provided over the prior 12 months. As of December 31, 2014, the Company has issued 1,456,035 shares of its common stock under this agreement and recorded expense of $1.9 million and $0.5 million in the years ended December 31, 2014 and 2013, respectively.
	Media Advertising Agreement
	In 2012, the Company entered into consulting agreements with a third-party entity for marketing and advertising services. In connection with these agreements, the Company paid the consultant $0.2 million, issued 500,000 registered shares of the Company’s common stock and issued 352,000 unregistered shares of the Company’s common stock. In May 2013, the Company entered into an additional consulting agreement with this third-party entity for marketing and advertising services. In connection with this additional agreement, the Company paid the consultant total cash consideration of $0.2 million and issued 225,000 restricted shares of the Company’s common stock. The Company recorded total stock compensation related to these agreements of less than $0.1 million during the year ended December 31, 2014 and $0.7 million and $1.1 million, respectively, during the years ended December 31, 2013 and 2012.
	Common Stock Reserved for Future Issuance
	Common stock reserved for future issuance consists of the following (in thousands):
		31-Dec-14
	Stock options outstanding	8,267
	Awards outstanding	690
	Performance restricted stock units outstanding	854
	Warrants outstanding	12,044
	Authorized for future grant under 2005 Plan	3,408
		25,263

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	The components of the pretax loss from operations for the years ended December 31, 2014, 2013 and 2012 are as follows (in thousands):
		Year Ended December 31,
		2014				2013				2012
	U.S. Domestic	$	(8,106	)		$	(9,264	)		$	(3,310	)
	Foreign	(3,689		)		(69,784		)		(13,308		)
	Pretax loss from operations	$	(11,795	)		$	(79,048	)		$	(16,618	)
	The components of the provision (benefit) for income taxes are presented in the following table (in thousands):
		Year Ended December 31,
		2014				2013				2012
	Current:
	Federal	$	—			$	(21	)		$	107
	State	145				186				24
	Foreign	526				2,525				2,083
	Total current provision (benefit)	671				2,690				2,214
	Deferred:
	Federal	238				229				137
	State	24				15				29
	Foreign	154				245				(3,539		)
	Total deferred provision (benefit)	416				489				(3,373		)
	Total provision (benefit)	$	1,087			$	3,179			$	(1,159	)
	The provision (benefit) for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate to pretax income as a result of the following differences:
		December 31,
		2014			2013			2012
	Federal statutory rate	(35.0	)%		(35.0	)%		(35.0	)%
	Adjustments for tax effects of:
	State taxes, net	(1.1	)%		(0.1	)%		—	%
	Stock-based compensation	6.2	%		0.5	%		(0.5	)%
	Foreign taxes	3.4	%		1.1	%		(0.1	)%
	Tax credits	(3.3	)%		(0.4	)%		(0.7	)%
	Deemed foreign dividend	—	%		—	%		0.2	%
	Fair market value adjustments	(7.6	)%		—	%		—	%
	Intercompany debt forgiveness and other permanent adjustments	3.1	%		9.5	%		5	%
	Tax rate adjustment	0.4	%		0.2	%		0.7	%
	Uncertain tax positions	5.3	%		2.7	%		14.9	%
	Other	0.2	%		(0.4	)%		3.3	%
	Valuation allowance	37.5	%		25.9	%		5.2	%
	Effective income tax rate	9.1	%		4	%		(7.0	)%
	The 2014 provision for income taxes primarily consists of an increase in unrecognized tax benefits associated with the European operations, tax expense related to non-income based state tax in the U.S. and current year income in Japan and Brazil, and an increase in the deferred tax liability related to tax-deductible goodwill in the U.S.
	Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2014 and 2013 are as follows (in thousands):
		December 31,
		2014				2013
	Deferred tax assets:
	Allowances and reserves	$	818			$	816
	Accrued expenses	3,674				3,685
	Inventory reserves	8,532				7,549
	Net operating loss carryforwards	41,965				26,497
	Property and equipment	1,976				1,171
	Stock-based compensation	2,168				2,769
	Legal settlement	1,204				17,998
	Income tax credit carryforwards	2,218				1,800
	Total deferred tax assets	62,555				62,285
	Valuation allowance	(58,781		)		(56,690		)
	Total deferred tax assets, net of valuation allowance	3,774				5,595
	Deferred tax liabilities:
	Property and equipment	—				—
	Intangible assets	2,881				4,806
	Goodwill	1,518				1,256
	Total deferred tax liabilities	4,399				6,062
	Net deferred tax assets (liabilities)	$	(625	)		$	(467	)
	The realization of deferred tax assets may be dependent on the Company’s ability to generate sufficient income in future years in the associated jurisdiction to which the deferred tax assets relate. As of December 31, 2014, a valuation allowance of $58.8 million has been established against the net deferred tax assets as realization is uncertain. The net deferred tax assets primarily consist of Japanese deferred tax assets. The deferred tax liabilities consist of tax-deductible goodwill in the U.S. Deferred tax liabilities associated with tax-deductible goodwill cannot be considered a source of income to support the realization of deferred tax assets because the reversal of these deferred tax liabilities is considered indefinite. At December 31, 2014, such amounts represent $1.5 million.
	In determining the need for a valuation allowance the Company considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance. Based on the review of all positive and negative evidence, including a three year cumulative pre-tax loss, the Company determined that a full valuation allowance should be recorded against all U.S. and European deferred tax assets at December 31, 2014. During 2012, it was determined that the Company was more-likely-than-not to realize its Japanese deferred tax assets. The Company removed the valuation allowance on the Japanese deferred tax assets and recognized a tax benefit of $1.4 million in 2012. In the event that the Company determines that it would not be able to realize all or part of its Japanese deferred tax assets in the future, it would increase the valuation allowance and recognize a corresponding tax provision in the period in which it made such a determination. Likewise, if the Company later determines that it is more-likely-than-not to realize all or a portion of the U.S. or European deferred tax assets, it would reverse the previously provided valuation allowance.
	At December 31, 2014, the Company has unrecognized tax benefits of $8.9 million of which $8.1 million will affect the effective tax rate if recognized when the Company no longer has a valuation allowance offsetting its deferred tax assets.
	The following table summarizes the changes to unrecognized tax benefits for the years ended December 31, 2014, 2013 and 2012 (in thousands):
Balance at December 31, 2011	$	4,197
Additions based on tax positions related to the prior year	987
Additions based on tax positions related to the current year	743
Reductions as a result of lapse of applicable statute of limitations	(58		)
Additions as a result of foreign exchange rates and other	28
Balance at December 31, 2012	$	5,897
Additions based on tax positions related to the prior year	221
Additions based on tax positions related to the current year	1,664
Reductions as a result of lapse of applicable statute of limitations	(20		)
Additions as a result of foreign exchange rates and other	73
Balance at December 31, 2013	$	7,835
Additions based on tax positions related to the prior year	391
Additions based on tax positions related to the current year	1,050
Reductions as a result of lapse of applicable statute of limitations	(40		)
Reductions as a result of foreign exchange rates and other	(375		)
Balance at December 31, 2014	$	8,861
The Company believes it is reasonably possible it will not materially reduce its unrecognized tax benefits within the next 12 months.
The Company and its subsidiaries are subject to federal income tax as well as income tax of multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to income tax examination by tax authorities in major jurisdictions for years prior to 2009. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses and tax credits were generated and carried forward, and make adjustments up to the amount of the carryforwards. The Company is not currently under examination by the Internal Revenue Service, foreign or state and local tax authorities.
The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision. As of December 31, 2014, accrued interest and penalties were $1.3 million, which primarily relates to the uncertain tax positions of the Scient’x operations. During 2014, there was an increase of $0.2 million in the accrued interest and penalties related to the uncertain tax positions of the Scient’x operations.
At December 31, 2014, the Company had federal and state net operating loss carryforwards of $45.5 million and $56.6 million, respectively, expiring at various dates through 2034. At December 31, 2014, the Company had federal and state research and development tax credits of $3.1 million and $2.8 million, respectively. The federal research and development tax credits expire at various dates through 2034, while the state credits do not expire. The Company had foreign net operating loss carryforwards of $84.6 million beginning to expire in 2018. Utilization of the net operating loss and tax credit carryforwards may become subject to annual limitations due to ownership change limitations that could occur in the future as provided by Section 382 of the Internal Revenue Code of 1986, as amended, as well as similar state and foreign provisions. These ownership changes may limit the amount of the net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income. An ownership change occurred during June 2006 in connection with the initial public offering. The annual limitation as a result of that ownership change did not result in the loss or substantial limitation of net operating loss or tax credit carryforwards. There have been no subsequent ownership changes through December 31, 2014.
The Company does not record U.S. income taxes on the undistributed earnings of its foreign subsidiaries based upon the Company’s intention to permanently reinvest undistributed earnings to ensure sufficient working capital and further expansion of existing operations outside the United States. The undistributed earnings of the foreign subsidiaries as of December 31, 2014 are immaterial. In the event the Company is required to repatriate funds from outside of the United States, such repatriation would be subject to local laws, customs, and tax consequences.

Segment_and_Geographical_Infor

Segment and Geographical Information	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment and Geographical Information	Segment and Geographical Information
	Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in one reportable business segment.
	During the years ended December 31, 2014, 2013 and 2012, the Company operated in two geographic regions, the U.S. and International regions. The International region consists of locations outside of the U.S. In the International geographic location, sales in Japan for the years ended December 31, 2014, 2013 and 2012 totaled $31.9 million, $28.0 million and $28.6 million, respectively, which represented greater than 10 percent of the Company’s consolidated revenues for the years then ended December. For the years ended December 31, 2014, 2013 and 2012, sales in other individual countries included in the International region did not exceed 10 percent of consolidated revenues.
	Revenues attributed to the geographic location of the customer were as follows (in thousands):
		Year Ended December 31,
		2014		2013		2012
	United States	$	137,060	$	134,951	$	130,476
	International	69,920		69,773		65,802
	Total consolidated revenues	$	206,980	$	204,724	$	196,278
	Total assets by geographic region were as follows (in thousands):
		December 31,
		2014		2013
	United States	$	200,978	$	196,383
	International	143,945		169,247
	Total consolidated assets	$	344,923	$	365,630

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions
	For the years ended December 31, 2014, 2013 and 2012, the Company incurred costs of $0.2 million, $0.2 million and $0.2 million, respectively, to Foster Management Company and HealthpointCapital, LLC for travel and administrative expenses. John H. Foster is a significant equity holder of HealthpointCapital, LLC, an affiliate of HealthpointCapital Partners, L.P. and HealthpointCapital Partners II, L.P., which are the Company’s principal stockholders.
	Indemnification Agreements
	The Company has entered into indemnification agreements with certain of its directors, which are named defendants in the Orthotec litigation matter in New York (See Note 7 - Commitments and Contingencies - Litigation). The indemnification agreements require the Company to indemnify these individuals to the fullest extent permitted by applicable law and to advance expenses incurred by them in connection with any proceeding against them with respect to which they may be entitled to indemnification by the Company. For the years ended December 31, 2014 and 2013, the Company paid less than $0.1 million and $1.7 million, respectively, in connection with the indemnification obligations of Scient’x and Surgiview, all of which was related to the Orthotec matter. (See Note 7).

Retirement_Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Retirement Plan	Retirement Plan
	The Company maintains an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code. Under the savings plan, participating employees may contribute a portion of their pre-tax earnings, up to the Internal Revenue Service annual contribution limit. Additionally, the Company may elect to make matching contributions into the savings plan at its sole discretion of up to 4% of each individual’s compensation. Matching contributions vest after one year of service. The Company’s total contributions to the 401(k) plan were $0.6 million, $0.6 million and $0.5 million for the years ended December 31, 2014, 2013 and 2012, respectively.

Restructuring_Activities

Restructuring Activities	12 Months Ended
	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Restructuring Activities	Restructuring Activities
	On September 16, 2013, the Company announced that Scient'x began a process to significantly restructure its business operations in France in an effort to improve operating efficiencies and rationalize its cost structure. The restructuring included a reduction in Scient'x's workforce and closing of the manufacturing facilities in France. The Company has recorded total costs of $10.4 million through December 31, 2014 associated with this restructuring, which includes employee severance, social plan benefits and related taxes, facility closing costs, manufacturing transfer costs, and contract termination costs. In accordance with ASC Topic 420, Accounting for Costs Associated with Exit or Disposal Activities, and ASC Topic 712, Non retirement Postemployment Benefits, the Company recorded a restructuring charge accrual in accrued expenses of $0.5 million and $9.2 million within the consolidated balance sheets as of December 31, 2014 and 2013, respectively. Additionally, the Company has recorded restructuring expenses of $0.7 million within the consolidated statements of operations for the year ended December 31, 2014. The Company has substantially completed the activities associated with the restructuring as of December 31, 2014, and a substantial portion has been paid.
	In connection with the restructuring plan, the Company modified its estimate of inventory and instrument net book value at its Scient'x entities based on revised global demand. The Company recorded an additional inventory reserve of $4.9 million in the year ended December 31, 2013 which is included in cost of goods sold within the consolidated statements of operations.
	Below is a table of the movement (in thousands):
		Accrued Balance at		Expensed		Paid and			Accrued Balance at		Total Costs
		31-Dec-13		December 31, 2014		Other			31-Dec-14		Incurred
	Social plan costs	$	9,170	$	197	$	(8,836	)	$	531	$	9,450
	Other restructuring costs	—		509		(509		)	—		921
	Total	$	9,170	$	706	$	(9,345	)	$	531	$	10,371

Cross_Medical

Cross Medical	12 Months Ended
	Dec. 31, 2014
Cross Medical [Abstract]
Cross Medical	Cross Medical
	On February 12, 2010, a complaint was filed in the U.S. District Court for the Central District of California, by Cross Medical Products, LLC, or Cross, (a subsidiary of Biomet), Cross Medical Products, LLC v. Alphatec Spine, Inc., Case No. 8:10-cv-176-MRP -MLG, alleging that we breached a patent license agreement with Cross by failing to make certain royalty payments allegedly due under the agreement. Cross was seeking payment of prior royalties allegedly due from the Company’s sales of polyaxial screws and an order from the court regarding payment of future royalties by us. In its complaint, Cross alleged a material amount of damages were due to it as a result of our alleged breach of the patent license agreement.
	In January 2011, we filed a complaint in the U.S. District Court for the Southern District of California against Biomet, Inc., or Biomet, alleging that Biomet’s TPS-TL products infringe one of our patents. On December 30, 2011, we reached a global settlement agreement of the pending lawsuits with Biomet and Cross. Under the terms of the settlement, all parties obtained a release of all claims that were the subject of the disputes. No party has admitted liability in connection with the settlement. The settlement also includes an amendment to the April 23, 2003 License Agreement.
	As part of the settlement, we agreed to pay Cross an initial payment of $5 million, which payment was made in January 2012. In addition to the initial payment, we agreed to make thirteen quarterly payments of $1 million beginning on August 1, 2012, with each subsequent payment due three months thereafter until the final payment is made in August 2015. The remaining cash obligations totaling $3 million as of December 31, 2014, will be paid in 2015. In addition, pursuant to the settlement, the parties have exchanged covenants not to sue for patent infringement with respect to products that each respective company had on the market as of December 30, 2011.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (Unaudited)	Quarterly Financial Data (Unaudited)
	The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for fiscal 2014 and 2013 are as follows (in thousands, except per share data):
		Year ended December 31, 2014
		1st			2nd			3rd			4th
		Quarter			Quarter			Quarter			Quarter
	Selected quarterly financial data:
	Revenue	$	49,173		$	53,167		$	51,013		$	53,627
	Gross profit	33,294			36,120			36,306			37,690
	Total operating expenses	37,996			34,279			34,574			34,717
	Net loss	(6,673		)	(2,895		)	(3,041		)	(273		)
	Net loss per basic share (1)	(0.07		)	(0.03		)	(0.03		)	0
	Net loss per diluted share (1)	(0.07		)	(0.03		)	(0.04		)	(0.03		)
		Year ended December 31, 2013
		1st			2nd			3rd			4th
		Quarter			Quarter			Quarter			Quarter
	Selected quarterly financial data:
	Revenue	$	50,443		$	51,020		$	50,196		$	53,065
	Gross profit	32,742			32,093			24,232			35,255
	Total operating expenses	34,100			34,992			37,406			91,257
	Net loss	(2,649		)	(4,661		)	(14,510		)	(60,407		)
	Net loss per basic and diluted share (1)	(0.03		)	(0.05		)	(0.15		)	(0.62		)
	-1	Basic and diluted net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal the total for the year.

SCHEDULE_IIVALUATION_AND_QUALI

SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
		Allowance			Reserve for
		for			Excess and
		Doubtful			Obsolete
		Accounts (1)			Inventories (2)
		(In thousands)
	Balance at December 31, 2011	$	1,055		$	13,174
	Provision	859			6,658
	Write-offs and recoveries, net	(840		)	(2,610		)
	Balance at December 31, 2012	1,074			17,222
	Provision	404			11,652
	Write-offs and recoveries, net	(430		)	(4,928		)
	Balance at December 31, 2013	1,048			23,946
	Provision	522			3,539
	Write-offs and recoveries, net	(777		)	(6,160		)
	Balance at December 31, 2014	$	793		$	21,325
	-1	The provision is included in selling expenses.
	-2	The provision is included in cost of revenues.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts in the Company’s consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Concentrations of Credit Risk and Significant Customers	Concentrations of Credit Risk and Significant Customers
	Financial instruments, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and accounts receivable. The Company limits its exposure to credit loss by depositing its cash with established financial institutions. As of December 31, 2014 a substantial portion of the Company’s available cash funds is held in business accounts. Although the Company deposits its cash with multiple financial institutions, its deposits, at times, may exceed federally insured limits.
	The Company’s customers are primarily hospitals, surgical centers and distributors and no single customer represented greater than 10 percent of consolidated revenues for any of the periods presented. Credit to customers is granted based on an analysis of the customers’ credit worthiness and credit losses have not been significant.
Revenue Recognition	Revenue Recognition
	The Company derives its revenues primarily from the sale of spinal surgery implants used in the treatment of spine disorders. The Company sells its products primarily through its direct sales force and independent distributors. Revenue is recognized when all four of the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectability is reasonably assured. In addition, the Company accounts for revenue under provisions which set forth guidelines for the timing of revenue recognition based upon factors such as passage of title, installation, payment and customer acceptance.
	The Company’s revenue from sales of spinal and other surgical implant products is recognized upon receipt of written acknowledgment that the product has been used in a surgical procedure or upon shipment to third-party customers who immediately accept title to such product.
Deferred Revenues	Deferred revenues consist of sales transactions where circumstances indicate that colectibility is not reasonably assured due to payment terms, regional market risks or customer history. The Company defers the recognition of revenue until payments become due and cash is received from these distributors.
Restricted Cash	Restricted Cash
	In March and November 2014, the Company borrowed and set aside cash for the payment of a portion of the Orthotec litigation settlement, which is subject to the terms of the facility agreement that it entered into with Deerfield on March 17, 2014. The Company classified this cash as restricted, because it may not be used for purposes other than payments of amounts due under the Orthotec litigation settlement agreement.
Accounts Receivable	Accounts Receivable
	Accounts receivable are presented net of allowance for doubtful accounts. The Company makes judgments as to its ability to collect outstanding receivables and provides allowances for a portion of receivables when collection becomes doubtful. Provisions are made based upon a specific review of all significant outstanding invoices and the overall quality and age of those invoices not specifically reviewed. In determining the provision for invoices not specifically reviewed, the Company analyzes historical collection experience. If the historical data used to calculate the allowance provided for doubtful accounts does not reflect the Company’s future ability to collect outstanding receivables or if the financial condition of customers were to deteriorate, resulting in impairment of their ability to make payments, an increase in the provision for doubtful accounts may be required.
Inventories	Inventories
	Inventories are stated at the lower of cost or market, with cost primarily determined under the first-in, first-out method. The Company reviews the components of inventory on a periodic basis for excess, obsolete and impaired inventory, and records a reserve for the identified items. The Company calculates an inventory reserve for estimated excess and obsolete inventory based upon historical turnover and assumptions about future demand for its products and market conditions. The Company’s biologics inventories have an expiration based on shelf life and are subject to demand fluctuations based on the availability and demand for alternative implant products. The Company’s estimates and assumptions for excess and obsolete inventory are reviewed and updated on a quarterly basis. Increases in the reserve for excess and obsolete inventory result in a corresponding increase to cost of revenues and establish a new cost basis for the part.
Property and Equipment	Property and Equipment
	Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, generally ranging from three to seven years. Leasehold improvements and assets acquired under capital leases are amortized over the shorter of their useful lives or the terms of the related leases.
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets
	The Company accounts for goodwill and other intangible assets in accordance with provisions which require that goodwill and other identifiable intangible assets with indefinite useful lives be tested for impairment at least annually. The Company tests goodwill and intangible assets for impairment in December of each year, or more frequently if events and circumstances warrant. These assets are impaired if the Company determines that their carrying values may not be recoverable based on an assessment of certain events or changes in circumstances. If the assets are considered to be impaired, the Company recognizes the amount by which the carrying value of the assets exceeds the fair value of the assets as an impairment loss. During the year ended December 31, 2013, the Company decided that it would not continue to market an adult stem cell product sold under the Company's private label name of PureGen. The Company also decided that it would no longer actively market two additional products. The Company expensed $1.3 million as impairment charges in cost of goods sold in the year ended December 31, 2013 for the write-off of intangible assets related to these products.
	The Company estimated the fair value in step one of the goodwill impairment test based on a combination of the income approach which included discounted cash flows as well as a market approach that utilized the Company’s market information. The income approach fair value measurements are categorized within Level 3 of the fair value hierarchy. The Company’s discounted cash flows required management judgment with respect to forecasted sales, launch of new products, gross margin, selling, general and administrative expenses, capital expenditures and the selection and use of an appropriate discount rate and terminal rate. For purposes of calculating the discounted cash flows, the Company used estimated revenue growth rates averaging between 4% and 7% for the discrete forecast period. Cash flows beyond the discrete forecasts were estimated using a terminal value calculation, which incorporated historical and forecasted financial trends and considered long-term earnings growth rates for publicly traded peer companies. Future cash flows were then discounted to present value at a discount rate of 11.5%, and terminal value growth rate of 4%. Publicly available information regarding comparable market capitalization was also considered in assessing the reasonableness of the Company’s fair value. The Company’s assessment resulted in a fair value that was greater than the Company’s carrying value at December 31, 2014. In accordance with the authoritative literature, the second step of the impairment test was not required to be performed and thus no impairment of goodwill was recorded as of December 31, 2014.
	Significant management judgment is required in the forecast of future operating results that are used in the Company’s impairment analysis. The estimates the Company used are consistent with the plans and estimates that it uses to manage its business. Significant assumptions utilized in the Company’s income approach model included the growth rate of sales for recently introduced products and the introduction of anticipated new products similar to its historical growth rates. Another important assumption involved in forecasted sales is the projected mix of higher margin U.S. based sales and lower margin non-U.S. based sales. Additionally, the Company has projected an improvement in its gross margin, similar to its historical improvement in gross margins, as a result of its forecasted mix in U.S. sales versus non-U.S. sales and lower manufacturing cost per unit based on the increase in forecasted volume to absorb applied overhead over the next ten years. Although the Company believes its underlying assumptions supporting this assessment are reasonable, if the Company’s forecasted sales, mix of product sales, growth rates of recently introduced new products, timing of and growth rates of new product introductions, gross margin, selling, general and administrative expenses, or the discount rate vary from its forecasts, the Company could be exposed to material impairment charges in the future. Additionally, if the Company’s stock price decreases significantly from the closing price on December 31, 2014, the Company may be required to perform an interim analysis in 2015 that could result in an impairment charge.
	The accounting provisions also require that intangible assets with definite useful lives be amortized over their respective estimated useful lives and reviewed for indicators of impairment. The Company is amortizing its intangible assets, other than goodwill, on a straight-line basis over a one to fifteen-year period.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	The Company assesses potential impairment to its long-lived assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the carrying amount of the long-lived assets is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Any required impairment loss is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value and is recorded as a reduction in the carrying value of the related asset and a charge to operating results.
Foreign Currency	Foreign Currency
	The Company’s results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates. The Company’s primary functional currency is the U.S. dollar, while the functional currency of the Company’s foreign subsidiaries are the Japanese Yen, the Euro, the Brazilian Real, the British Pound and the Hong Kong dollar. Assets and liabilities denominated in foreign currencies are translated at the rate of exchange on the balance sheet date. Revenues and expenses are translated using the average exchange rate for the period. Net gains and losses resulting from the translation of foreign financial statements are recorded as accumulated other comprehensive income (loss) in stockholders’ equity. Net foreign currency gains or (losses) resulting from transactions in currencies other than the functional currencies are included in other income (expense), net in the accompanying consolidated statements of operations.
Warrants to Purchase Common Stock	Warrants to Purchase Common Stock
	Common stock warrants that contain compliance covenants and cash payment obligations are classified as common stock warrant liabilities on the consolidated balance sheet. The Company records the warrant liability at fair value and adjusts the carrying value of these common stock warrants to their estimated fair value at each reporting date with the increases or decreases in the fair value of such warrants at each reporting date recorded as other income (expense) in the consolidated statement of operations.
Research and Development	Research and Development
	Research and development expense consists of costs associated with the design, development, testing, and enhancement of the Company’s products. Research and development costs also include salaries and related employee benefits, research-related overhead expenses, fees paid to external service providers, and costs associated with the Company’s Scientific Advisory Board and Executive Surgeon Panels. Research and development costs are expensed as incurred.
In-Process Research and Development	In-Process Research and Development
	In-process research and development (“IPR&D”) consists of acquired research and development assets that are not part of an acquisition of a business and were not technologically feasible on the date the Company acquired them and had no alternative future use at that date or assets acquired in a business acquisition that are determined to have no alternative future use. The Company expects all acquired IPR&D will reach technological feasibility, but there can be no assurance that commercial viability of these products will ever be achieved. The nature of the efforts to develop the acquired technologies into commercially viable products consists principally of planning, designing, developing and testing products in order to obtain regulatory approvals. If commercial viability were not achieved, the Company would likely look to other alternatives to provide these products. Until the technological feasibility of the acquired research and development assets are established, the Company expenses these costs.
Leases	Leases
	The Company leases its facilities and certain equipment and vehicles under operating leases, and certain equipment under capital leases. For facility leases that contain rent escalation or rent concession provisions, the Company records the total rent payable during the lease term on a straight-line basis over the term of the lease. The Company records the difference between the rent paid and the straight-line rent as a deferred rent liability in the accompanying consolidated balance sheets.
Product Shipment Cost	Product Shipment Cost
	Product shipment costs are included in sales and marketing expense in the accompanying consolidated statements of operations.
Stock-Based Compensation	Stock-Based Compensation
	The Company accounts for stock-based compensation under provisions which require that share-based payment transactions with employees be recognized in the financial statements based on their fair value and recognized as compensation expense over the vesting period. The amount of expense recognized during the period is affected by subjective assumptions, including: estimates of the Company’s future volatility, the expected term for its stock options, the number of options expected to ultimately vest, and the timing of vesting for the Company’s share-based awards.
	The Company uses a Black-Scholes option-pricing model to estimate the fair value of its stock option awards. The calculation of the fair value of the awards using the Black-Scholes option-pricing model is affected by the Company’s common stock price on the date of grant as well as assumptions regarding the following:
	•	Estimated volatility is a measure of the amount by which the Company’s common stock price is expected to fluctuate each year during the expected life of the award. The Company’s estimated volatility through December 31, 2014 was based on a weighted-average volatility of its actual historical volatility over a period equal to the expected life of the awards.
	•	The expected term represents the period of time that awards granted are expected to be outstanding. Through December 31, 2014, the Company calculated the expected term using a weighted-average term based on historical exercise patterns and the term from option date to full exercise for the options granted within the specified date range.
	•	The risk-free interest rate is based on the yield curve of a zero-coupon U.S. Treasury bond on the date the stock option award is granted with a maturity equal to the expected term of the stock option award.
	•	The assumed dividend yield is based on the Company’s expectation of not paying dividends in the foreseeable future.
	The Company used historical data to estimate the number of future stock option forfeitures. Share-based compensation recorded in the Company’s consolidated statement of operations is based on awards expected to ultimately vest and has been reduced for estimated forfeitures. The Company’s estimated forfeiture rates may differ from its actual forfeitures which would affect the amount of expense recognized during the period.
	The Company accounts for stock option grants to non-employees in accordance with provisions which require that the fair value of these instruments be recognized as an expense over the period in which the related services are rendered.
	Share-based compensation expense of awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met. Determining the likelihood and timing of achieving performance conditions is a subjective judgment made by management which may affect the amount and timing of expense related to these share-based awards. Share-based compensation is adjusted to reflect the value of options which ultimately vest as such amounts become known in future periods.
	Valuation of Stock Option Awards
	The assumptions used to compute the share-based compensation costs for the stock options granted during the years ended December 31, 2014, 2013 and 2012 are as follows:
		Year Ended December 31,
		2014		2013			2012
	Risk-free interest rate	1.8-1.9%		1.1-1.8%			0.9-1.2%
	Expected dividend yield	—		—			—
	Weighted average expected life (years)	5.4-5.5		5.3-5.5			5.3-5.8
	Volatility	60-71%		75-76%			75-78%
	Compensation Costs
	The compensation cost that has been included in the Company’s consolidated statement of operations for all stock-based compensation arrangements is detailed as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Cost of revenues	$	274		$	228		$	137
	Research and development	2,080			719			261
	Sales and marketing	470			459			1,695
	General and administrative	1,730			2,672			1,447
	Total	$	4,554		$	4,078		$	3,540
	The amounts provided above include stock-based compensation expense of $1.9 million, $1.5 million and $1.3 million during the years ended December 31, 2014, 2013 and 2012, respectively, related to the vesting of stock options and awards granted to non-employees under consulting agreements.
	Stock-Based Compensation
	The Company accounts for stock-based compensation under provisions which require that share-based payment transactions with employees be recognized in the financial statements based on their fair value and recognized as compensation expense over the vesting period. The amount of expense recognized during the period is affected by subjective assumptions, including: estimates of the Company’s future volatility, the expected term for its stock options, the number of options expected to ultimately vest, and the timing of vesting for the Company’s share-based awards.
	The Company uses a Black-Scholes option-pricing model to estimate the fair value of its stock option awards. The calculation of the fair value of the awards using the Black-Scholes option-pricing model is affected by the Company’s common stock price on the date of grant as well as assumptions regarding the following:
	•	Estimated volatility is a measure of the amount by which the Company’s common stock price is expected to fluctuate each year during the expected life of the award. The Company’s estimated volatility through December 31, 2014 was based on a weighted-average volatility of its actual historical volatility over a period equal to the expected life of the awards.
	•	The expected term represents the period of time that awards granted are expected to be outstanding. Through December 31, 2014, the Company calculated the expected term using a weighted-average term based on historical exercise patterns and the term from option date to full exercise for the options granted within the specified date range.
	•	The risk-free interest rate is based on the yield curve of a zero-coupon U.S. Treasury bond on the date the stock option award is granted with a maturity equal to the expected term of the stock option award.
	•	The assumed dividend yield is based on the Company’s expectation of not paying dividends in the foreseeable future.
	The Company used historical data to estimate the number of future stock option forfeitures. Share-based compensation recorded in the Company’s consolidated statement of operations is based on awards expected to ultimately vest and has been reduced for estimated forfeitures. The Company’s estimated forfeiture rates may differ from its actual forfeitures which would affect the amount of expense recognized during the period.
	The Company accounts for stock option grants to non-employees in accordance with provisions which require that the fair value of these instruments be recognized as an expense over the period in which the related services are rendered.
	Share-based compensation expense of awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met. Determining the likelihood and timing of achieving performance conditions is a subjective judgment made by management which may affect the amount and timing of expense related to these share-based awards. Share-based compensation is adjusted to reflect the value of options which ultimately vest as such amounts become known in future periods.
Income Taxes	he amounts provided above include stock-based compensation expense of $1.9 million, $1.5 million and $1.3 million during the years ended December 31, 2014, 2013 and 2012, respectively, related to the vesting of stock options and awards granted to non-employees under consulting agreements.
	Income Taxes
	The Company accounts for income taxes in accordance with provisions which set forth an asset and liability approach that requires the recognition of deferred tax assets and deferred tax liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. In making such determination, a review of all available positive and negative evidence must be considered, including scheduled reversal of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance.
	The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision.
Net Loss per Share	Net Loss per Share
	Basic earnings per share (“EPS”) is calculated by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted EPS is computed by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period and the weighted average number of dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, common stock subject to repurchase by the Company and options are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share when their effect is dilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In March 2013, the Financial Accounting Standards Board (“FASB”) issued guidance on a parent company’s accounting for the cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. This new guidance requires that the parent release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. The amendments became effective for the Company beginning January 1, 2014. The Company adopted this guidance and the adoption did not have any impact on the Company's financial statements.
	In April 2014, the FASB issued new guidance related to reporting discontinued operations. This new standard raises the threshold for a disposal to qualify as a discontinued operation and requires new disclosures of both discontinued operations and certain other disposals that do not meet the definition of a discontinued operation. The new standard is effective for fiscal years beginning on or after December 15, 2014. The Company is evaluating the impact, if any, of adopting this new accounting standard on its financial statements.
	In May 2014, the FASB issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for the Company beginning January 1, 2017 and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is evaluating the impact of adopting this new accounting standard on its financial statements.
	In August 2014, the FASB issued guidance related to disclosures of uncertainties about an entity’s ability to continue as a going concern. The guidance requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued. Management will be required to make this evaluation for both annual and interim reporting periods and will have to make certain disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the entity’s ability to continue as a going concern. Substantial doubt exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued. The guidance is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter 2017, with early adoption permitted. The Company is evaluating the impact of this guidance and expects to adopt the standard for the annual reporting period ending December 31, 2016.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements
	The carrying amount of financial instruments consisting of cash, restricted cash, trade accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses, accrued compensation and current portion of long-term debt included in the Company’s consolidated financial statements are reasonable estimates of fair value due to their short maturities. Based on the borrowing rates currently available to the Company for loans with similar terms, management believes the fair value of long-term debt approximates its carrying value.
	Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level 1:	Observable inputs such as quoted prices in active markets;
	Level 2:	Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3:	Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	The Company does not maintain any financial instruments that are considered to be Level 1 or Level 2 instruments as of December 31, 2014 or December 31, 2013. The Company classifies its common stock warrant liabilities within Level 3 of the fair value hierarchy because they are valued using valuation models with significant unobservable inputs.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a reconciliation of liabilities measured at fair value using significant unobservable inputs (Level 3) for the year ended December 31, 2014 (in thousands):
		Common Stock Warrant Liabilities
	Balance at December 31, 2013	$	—
	Issuance	11,280
	Changes in fair value	(2,578		)
	Balance at December 31, 2014	$	8,702
Summary of Assumptions Used to Compute Share-Based Compensation Costs for Stock Options Granted	The assumptions used to compute the share-based compensation costs for the stock options granted during the years ended December 31, 2014, 2013 and 2012 are as follows:
		Year Ended December 31,
		2014			2013			2012
	Risk-free interest rate	1.8-1.9%			1.1-1.8%			0.9-1.2%
	Expected dividend yield	—			—			—
	Weighted average expected life (years)	5.4-5.5			5.3-5.5			5.3-5.8
	Volatility	60-71%			75-76%			75-78%
Summary of Compensation Cost for Stock-Based Compensation Arrangements	The compensation cost that has been included in the Company’s consolidated statement of operations for all stock-based compensation arrangements is detailed as follows (in thousands):
		Year Ended December 31,
		2014				2013			2012
	Cost of revenues	$	274			$	228		$	137
	Research and development	2,080				719			261
	Sales and marketing	470				459			1,695
	General and administrative	1,730				2,672			1,447
	Total	$	4,554			$	4,078		$	3,540
Weighted Average Number of Common Shares Outstanding	For purposes of this calculation, common stock subject to repurchase by the Company and options are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share when their effect is dilutive. (In thousands, except per share data):
		Year Ended December 31,
		2014				2013			2012
	Numerator:
	Net loss for basic earnings per share	$	(12,882	)		$	(82,227	)	$	(15,459	)
	Decrease in fair value of warrants	(2,578		)		—			—
	Diluted net loss applicable to common stockholders	$	(15,460	)		$	(82,227	)	$	(15,459	)
	Denominator:
	Weighted average common shares outstanding	98,138				97,111			90,870
	Weighted average unvested common shares subject to repurchase	(791		)		(876		)	(652		)
	Weighted average common shares outstanding—basic	97,347				96,235			90,218
	Effect of dilutive securities:
	Conversion of preferred stock	—				—			—
	Options	—				—			—
	Warrants	388				—			—
	Weighted average common shares outstanding—diluted	97,735				96,235			90,218
	Net loss per share:
	Basic	$	(0.13	)		$	(0.85	)	$	(0.17	)
	Diluted	$	(0.16	)		$	(0.85	)	$	(0.17	)
Weighted-Average Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share	The weighted-average anti-dilutive securities not included in diluted net loss per share were as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Options to purchase common stock	7,057			4,597			4,621
	Warrants to purchase common stock	725			594			476
	Unvested restricted stock awards	791			876			652
		8,573			6,067			5,749

Balance_Sheet_Details_Tables

Balance Sheet Details (Tables)	12 Months Ended
	Dec. 31, 2014
Balance Sheet Related Disclosures [Abstract]
Accounts Receivable	Accounts receivable consist of the following (in thousands):
		December 31,
		2014				2013
	Accounts receivable	$	41,233			$	42,443
	Allowance for doubtful accounts	(793		)		(1,048		)
	Accounts receivables, net	$	40,440			$	41,395
Inventories	Inventories consist of the following (in thousands):
		31-Dec-14										31-Dec-13
		Gross				Reserve for				Net		Gross		Reserve for			Net
						excess and								excess and
						obsolete								obsolete
	Raw materials	$	5,020			$	—			$	5,020	$	4,375	$	—		$	4,375
	Work-in-process	1,032				—				1,032		531		—			531
	Finished goods	57,020				(21,325		)		35,695		60,979		(23,946		)	37,033
	Inventories	$	63,072			$	(21,325	)		$	41,747	$	65,885	$	(23,946	)	$	41,939
Property and Equipment	Property and equipment consist of the following (in thousands):
		Useful lives		December 31,
		(in years)		2014				2013
	Surgical instruments	4		$	62,872			$	62,636
	Machinery and equipment	7		15,382				14,692
	Computer equipment	3		3,180				3,357
	Office furniture and equipment	5		3,789				3,703
	Leasehold improvements	various		3,841				4,161
	Building	39		65				52
	Land	n/a		9				10
	Construction in progress	n/a		1,320				1,228
				90,458				89,839
	Less accumulated depreciation and amortization			(64,418		)		(61,809		)
	Property and equipment, net			$	26,040			$	28,030
Intangible Assets	Intangibles assets consist of the following (in thousands):
		Useful lives		December 31,
		(in years)		2014				2013
	Developed product technology	8-Mar		$	22,526			$	23,633
	Distribution rights	3		2,095				2,343
	Intellectual property	5		1,004				1,004
	License agreements	7-Jan		16,716				17,686
	Core technology	10		4,554				5,137
	Trademarks and trade names	9-Mar		3,559				3,920
	Customer-related	15-Dec		20,493				22,161
	Distribution network	12-Oct		4,027				4,027
	Physician education programs	10		2,802				3,160
	Supply agreement	10		225				225
				78,001				83,296
	Less accumulated amortization			(47,742		)		(44,232		)
	Intangible assets, net			$	30,259			$	39,064
Future Expected Amortization Expense Related to Intangible Assets	The future expected amortization expense related to intangible assets as of December 31, 2014 is as follows (in thousands):
	Year Ending December 31,
	2015	$	5,646
	2016	5,163
	2017	4,866
	2018	3,053
	2019	2,852
	Thereafter	8,679
	Total	$	30,259
Accrued Expenses	Accrued expenses consist of the following (in thousands):
		December 31,
		2014				2013
	Legal	$	967			$	2,139
	Accounting	1,262				928
	Severance	318				297
	Restructuring	531				9,170
	Sales milestones	107				1,828
	Accrued taxes	1,344				1,120
	Deferred rent	785				1,163
	Royalties	2,129				2,347
	Commissions	6,152				6,180
	Payroll and related	8,291				9,369
	Litigation settlements	7,393				22,600
	Accrued interest	946				—
	Other	5,168				5,855
	Total accrued expenses	$	35,393			$	62,996
Schedule of Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill from December 31, 2013 through December 31, 2014 were as follows (in thousands):
		2014				2013
	Balance at January 1,	$	183,004			$	180,838
	Change in Phygen goodwill	—				(1,610		)
	Effect of foreign exchange rate on goodwill	(11,671		)		3,776
	Balance at December 31,	$	171,333			$	183,004

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Long-Term Debt	Long-term debt consists of the following (in thousands):
		December 31,
		2014			2013
	Amended Credit Facility with MidCap	$	60,390		$	52,081
	Facility Agreement with Deerfield	26,000			—
	Note payable related to software license purchases	250			58
	Financing agreements for premiums on insurance policies	1,580			1,427
	Total	88,220			53,566
	Add: capital leases (See Note 7)	1,784			1,336
	Less: debt discount	(7,331		)	—
	Total	82,673			54,902
	Less: current portion of long-term debt	(8,076		)	(4,924		)
	Total long-term debt, net of current portion	$	74,597		$	49,978
Principal Payments on Debt	Principal payments on debt are as follows as of December 31, 2014 (in thousands):
	Year Ending December 31,
	2015	$	7,346
	2016	54,874
	2017	8,667
	2018	8,667
	2019	8,666
	Thereafter	—
	Total	88,220
	Add: capital lease principal payments	1,784
	Less: debt discount	(7,331		)
	Total	82,673
	Less: current portion of long-term debt	(8,076		)
	Long-term debt, net of current portion	$	74,597

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Annual Lease Payments	Future minimum annual lease payments under the Company’s operating and capital leases are as follows (in thousands):
	Year ending December 31,	Operating		Capital
	2015	$	3,150	$	846
	2016	1,829		787
	2017	377		347
	2018	73		—
	2019	8		—
	Thereafter	—		—
		$	5,437	1,980
	Less: amount representing interest			(196		)
	Present value of minimum lease payments			1,784
	Current portion of capital leases			(730		)
	Capital leases, less current portion			$	1,054

Equity_Transactions_Equity_Tra1

Equity Transactions Equity Transactions (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Schedule of Assumptions Used	At December 31, 2014, the Company's outstanding warrants were valued using the Black-Scholes option pricing model. This is a Level 3 measurement using the following assumptions:
		December 31, 2014
	Risk-free interest rate	1.8	%
	Dividend yield	—	%
	Expected volatility	61	%
	Expected life (years)	5.3

Stock_Benefit_Plans_and_StockB1

Stock Benefit Plans and Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Option Activity	A summary of the Company’s stock option activity under the 2005 Plan and related information is as follows (in thousands, except as indicated and per share data):
		Shares		Weighted		Weighted	Aggregate
				average		average	intrinsic
				exercise		remaining	value
				price		contractual
						term
						(in years)
	Outstanding at December 31, 2013	7,761		$	2.23	7.59	$	753
	Granted	2,019		$	1.42	—	—
	Exercised	(21	)	$	1.33	—	—
	Forfeited	(1,492	)	$	1.99	—	—
	Outstanding at December 31, 2014	8,267		$	2.08	7.35	$	71
	Options vested and exercisable at December 31, 2014	4,149		$	2.46	6.16	$	27
	Options vested and expected to vest at December 31, 2014	7,819		$	2.11	7.26	$	64
Summary of Information about Restricted Stock Awards Activity	The following table summarizes information about the restricted stock awards activity (in thousands, except as indicated and per share data):
		Shares		Weighted		Weighted
				average		average
				grant		remaining
				date fair		recognition
				value		period
						(in years)
	Unvested at December 31, 2013	807		$	1.88	2.3
	Awarded	493		$	1.32
	Vested	(155	)	$	2.25
	Forfeited	(455	)	$	1.57
	Unvested at December 31, 2014	690		$	1.6	1.83
Summary of Common Stock Reserved for Future Issuance	Common stock reserved for future issuance consists of the following (in thousands):
		31-Dec-14
	Stock options outstanding	8,267
	Awards outstanding	690
	Performance restricted stock units outstanding	854
	Warrants outstanding	12,044
	Authorized for future grant under 2005 Plan	3,408
		25,263

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Components of Pretax Loss from Operations	The components of the pretax loss from operations for the years ended December 31, 2014, 2013 and 2012 are as follows (in thousands):
		Year Ended December 31,
		2014				2013				2012
	U.S. Domestic	$	(8,106	)		$	(9,264	)		$	(3,310	)
	Foreign	(3,689		)		(69,784		)		(13,308		)
	Pretax loss from operations	$	(11,795	)		$	(79,048	)		$	(16,618	)
Components of Provision (Benefit) for Income Taxes	The components of the provision (benefit) for income taxes are presented in the following table (in thousands):
		Year Ended December 31,
		2014				2013				2012
	Current:
	Federal	$	—			$	(21	)		$	107
	State	145				186				24
	Foreign	526				2,525				2,083
	Total current provision (benefit)	671				2,690				2,214
	Deferred:
	Federal	238				229				137
	State	24				15				29
	Foreign	154				245				(3,539		)
	Total deferred provision (benefit)	416				489				(3,373		)
	Total provision (benefit)	$	1,087			$	3,179			$	(1,159	)
Schedule of Effective Income Tax Rate Reconciliation	The provision (benefit) for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate to pretax income as a result of the following differences:
		December 31,
		2014			2013			2012
	Federal statutory rate	(35.0	)%		(35.0	)%		(35.0	)%
	Adjustments for tax effects of:
	State taxes, net	(1.1	)%		(0.1	)%		—	%
	Stock-based compensation	6.2	%		0.5	%		(0.5	)%
	Foreign taxes	3.4	%		1.1	%		(0.1	)%
	Tax credits	(3.3	)%		(0.4	)%		(0.7	)%
	Deemed foreign dividend	—	%		—	%		0.2	%
	Fair market value adjustments	(7.6	)%		—	%		—	%
	Intercompany debt forgiveness and other permanent adjustments	3.1	%		9.5	%		5	%
	Tax rate adjustment	0.4	%		0.2	%		0.7	%
	Uncertain tax positions	5.3	%		2.7	%		14.9	%
	Other	0.2	%		(0.4	)%		3.3	%
	Valuation allowance	37.5	%		25.9	%		5.2	%
	Effective income tax rate	9.1	%		4	%		(7.0	)%
Significant Components of Company's Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2014 and 2013 are as follows (in thousands):
		December 31,
		2014				2013
	Deferred tax assets:
	Allowances and reserves	$	818			$	816
	Accrued expenses	3,674				3,685
	Inventory reserves	8,532				7,549
	Net operating loss carryforwards	41,965				26,497
	Property and equipment	1,976				1,171
	Stock-based compensation	2,168				2,769
	Legal settlement	1,204				17,998
	Income tax credit carryforwards	2,218				1,800
	Total deferred tax assets	62,555				62,285
	Valuation allowance	(58,781		)		(56,690		)
	Total deferred tax assets, net of valuation allowance	3,774				5,595
	Deferred tax liabilities:
	Property and equipment	—				—
	Intangible assets	2,881				4,806
	Goodwill	1,518				1,256
	Total deferred tax liabilities	4,399				6,062
	Net deferred tax assets (liabilities)	$	(625	)		$	(467	)
Summary of Changes to Unrecognized Tax Benefits	The following table summarizes the changes to unrecognized tax benefits for the years ended December 31, 2014, 2013 and 2012 (in thousands):
	Balance at December 31, 2011	$	4,197
	Additions based on tax positions related to the prior year	987
	Additions based on tax positions related to the current year	743
	Reductions as a result of lapse of applicable statute of limitations	(58		)
	Additions as a result of foreign exchange rates and other	28
	Balance at December 31, 2012	$	5,897
	Additions based on tax positions related to the prior year	221
	Additions based on tax positions related to the current year	1,664
	Reductions as a result of lapse of applicable statute of limitations	(20		)
	Additions as a result of foreign exchange rates and other	73
	Balance at December 31, 2013	$	7,835
	Additions based on tax positions related to the prior year	391
	Additions based on tax positions related to the current year	1,050
	Reductions as a result of lapse of applicable statute of limitations	(40		)
	Reductions as a result of foreign exchange rates and other	(375		)
	Balance at December 31, 2014	$	8,861

Segment_and_Geographical_Infor1

Segment and Geographical Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Revenues Attributed to Geographic Location of Customer	Revenues attributed to the geographic location of the customer were as follows (in thousands):
		Year Ended December 31,
		2014		2013		2012
	United States	$	137,060	$	134,951	$	130,476
	International	69,920		69,773		65,802
	Total consolidated revenues	$	206,980	$	204,724	$	196,278
Schedule of Assets by Geographic Region	Total assets by geographic region were as follows (in thousands):
		December 31,
		2014		2013
	United States	$	200,978	$	196,383
	International	143,945		169,247
	Total consolidated assets	$	344,923	$	365,630

Restructuring_Activities_Table

Restructuring Activities (Tables)	12 Months Ended
	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve Movement	Below is a table of the movement (in thousands):
		Accrued Balance at		Expensed		Paid and			Accrued Balance at		Total Costs
		31-Dec-13		December 31, 2014		Other			31-Dec-14		Incurred
	Social plan costs	$	9,170	$	197	$	(8,836	)	$	531	$	9,450
	Other restructuring costs	—		509		(509		)	—		921
	Total	$	9,170	$	706	$	(9,345	)	$	531	$	10,371

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Financial Data	The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for fiscal 2014 and 2013 are as follows (in thousands, except per share data):
		Year ended December 31, 2014
		1st			2nd			3rd			4th
		Quarter			Quarter			Quarter			Quarter
	Selected quarterly financial data:
	Revenue	$	49,173		$	53,167		$	51,013		$	53,627
	Gross profit	33,294			36,120			36,306			37,690
	Total operating expenses	37,996			34,279			34,574			34,717
	Net loss	(6,673		)	(2,895		)	(3,041		)	(273		)
	Net loss per basic share (1)	(0.07		)	(0.03		)	(0.03		)	0
	Net loss per diluted share (1)	(0.07		)	(0.03		)	(0.04		)	(0.03		)
		Year ended December 31, 2013
		1st			2nd			3rd			4th
		Quarter			Quarter			Quarter			Quarter
	Selected quarterly financial data:
	Revenue	$	50,443		$	51,020		$	50,196		$	53,065
	Gross profit	32,742			32,093			24,232			35,255
	Total operating expenses	34,100			34,992			37,406			91,257
	Net loss	(2,649		)	(4,661		)	(14,510		)	(60,407		)
	Net loss per basic and diluted share (1)	(0.03		)	(0.05		)	(0.15		)	(0.62		)
	-1	Basic and diluted net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal the total for the year.

The_Company_and_Basis_of_Prese1

The Company and Basis of Presentation - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Market
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of market for products	50
Cash	$19,735,000	$21,345,000	$22,241,000	$20,666,000
Other working capital	$30,000,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended
Share data in Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 21, 2014
	Product
Significant Accounting Policies [Line Items]
Percentage of consolidated revenues held by customer	10.00%
Deferred revenue	$1,300,000	$1,009,000
Inventory at consigned location	17,300,000	18,400,000
Number of products no longer actively market	2
Impairment charges		1,300,000
Percentage of weighted average cost of capital discount rate	11.50%
Fair Value Inputs, Long-term Revenue Growth Rate	4.00%
Foreign currency gains	-1,000,000	-1,700,000	-900,000
Product shipment costs	3,700,000	3,100,000	2,900,000
Stock-based compensation expense	$1,900,000	$1,500,000	$1,300,000
Minimum [Member]
Significant Accounting Policies [Line Items]
Estimated useful lives of property and equipment	3 years
Fair Value Inputs, Long-term Revenue Growth Rate	4.00%
Intangible assets, amortization period	1 year
Maximum [Member]
Significant Accounting Policies [Line Items]
Estimated useful lives of property and equipment	7 years
Fair Value Inputs, Long-term Revenue Growth Rate	7.00%
Intangible assets, amortization period	15 years
Sales [Member] | Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, number of customers	0	0
Deerfield [Member]
Significant Accounting Policies [Line Items]
Number of warrants issued				1,200
Warrants issued on March 17th and March 20th [Member] | Deerfield [Member]
Significant Accounting Policies [Line Items]
Number of warrants issued	10,300

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Assumptions Used to Compute Share-Based Compensation Costs for Stock Options Granted (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum	1.80%	1.10%	0.90%
Risk-free interest rate, maximum	1.90%	1.80%	1.20%
Volatility, minimum	60.00%	75.00%	75.00%
Volatility, maximum	71.00%	76.00%	78.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average expected life (years)	5 years 4 months 18 days	5 years 3 months 18 days	5 years 3 months 18 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average expected life (years)	5 years 6 months 18 days	5 years 6 months 18 days	5 years 9 months 24 days

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Summary of Compensation Cost for Stock-Based Compensation Arrangements (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$4,554	$4,078	$3,540
Cost of revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	274	228	137
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2,080	719	261
Sales and marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	470	459	1,695
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$1,730	$2,672	$1,447

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Weighted Average Number of Common Shares Outstanding (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Numerator:
Net loss for basic earnings per share	($273)	($3,041)	($2,895)	($6,673)	($60,407)	($14,510)	($4,661)	($2,649)	($12,882)	($82,227)	($15,459)
Decrease in fair value adjustment of warrants									-2,578	0	0
Diluted net loss applicable to common stockholders									($15,460)	($82,227)	($15,459)
Denominator:
Weighted average common shares outstanding									98,138	97,111	90,870
Weighted average unvested common shares subject to repurchase									-791	-876	-652
Weighted average common shares outstanding—basic									97,347	96,235	90,218
Effect of dilutive securities:
Warrants									388
Weighted average common shares outstanding—diluted									97,735	96,235	90,218
Net loss per share:
Basic	$0	($0.03)	($0.03)	($0.07)					($0.13)	($0.85)	($0.17)
Diluted	($0.03)	($0.04)	($0.03)	($0.07)					($0.16)	($0.85)	($0.17)

Summary_of_Significant_Account7

Summary of Significant Accounting Policies - Weighted-Average Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share (Detail)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in diluted net loss per share	8,573	6,067	5,749
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in diluted net loss per share	7,057	4,597	4,621
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in diluted net loss per share	725	594	476
Unvested restricted stock awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in diluted net loss per share	791	876	652

Acquisitions_and_Investment_Ad

Acquisitions and Investment - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended
In Millions, except Share data, unless otherwise specified	Nov. 06, 2012	Nov. 30, 2013	Nov. 06, 2013	Apr. 30, 2013	Dec. 31, 2012
Business Acquisition [Line Items]
Closing price of share	$1.69
Phygen, LLC [Member]
Business Acquisition [Line Items]
Effective acquisition date	6-Nov-12
Number of shares issued to acquire business after reducing acquisition fees and expenses	4,069,087
Cash paid at closing of Purchase Agreement	$2
Unregistered shares of common stock placed in escrow account	1,170,960
Length of time following closing to keep security against potential indemnification obligations	12 months
Number of common stock claimed against escrow shares		328,356
Income related to common stock claimed against escrow shares		0.6
Business acquisition cost of acquired entity shares held in escrow and released	842,604
Cash paid to set-off for indemnification claims				4
Business acquisition, transaction related expenses					1.1
Total purchase price			18.5
Cash consideration paid			5.9
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable			8.9
Contingent consideration			$3.70

Balance_Sheet_Details_Accounts

Balance Sheet Details - Accounts Receivable (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]
Accounts receivable	$41,233	$42,443
Allowance for doubtful accounts	-793	-1,048
Accounts receivables, net	$40,440	$41,395

Balance_Sheet_Details_Inventor

Balance Sheet Details - Inventories (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]
Raw materials, Gross	$5,020	$4,375
Work-in-process, Gross	1,032	531
Finished goods, Gross	57,020	60,979
Inventories, Gross, Total	63,072	65,885
Reserve for excess and obsolete	21,325	23,946
Raw materials Net	5,020	4,375
Work-in-process, Net	1,032	531
Finished goods, Net	35,695	37,033
Inventories, Net, Total	$41,747	$41,939

Balance_Sheet_Details_Property

Balance Sheet Details - Property and Equipment (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, total	$90,458	$89,839
Less accumulated depreciation and amortization	-64,418	-61,809
Property and equipment, net	26,040	28,030
Surgical instruments [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	4 years
Property and equipment, total	62,872	62,636
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Property and equipment, total	15,382	14,692
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Property and equipment, total	3,180	3,357
Office furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Property and equipment, total	3,789	3,703
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Various useful life of property and equipment	various
Property and equipment, total	3,841	4,161
Building [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	39 years
Property and equipment, total	65	52
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, total	9	10
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, total	$1,320	$1,228

Balance_Sheet_Details_Addition

Balance Sheet Details - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Total depreciation expense	$12.20	$14.60	$14.20
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Capital leases	3.2	1.8
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Capital leases	$0.60	$0.60

Balance_Sheet_Details_Intangib

Balance Sheet Details - Intangible Assets (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	Product
Finite-Lived Intangible Assets [Line Items]
Developed product technology	$22,526,000	$23,633,000
Intellectual property	1,004,000	1,004,000
License agreements	16,716,000	17,686,000
Core technology	4,554,000	5,137,000
Trademarks and trade names	3,559,000	3,920,000
Customer-related	20,493,000	22,161,000
Distribution network	4,027,000	4,027,000
Physician education programs	2,802,000	3,160,000
Supply agreement	225,000	225,000
Intangible assets, Gross	78,001,000	83,296,000
Less accumulated amortization	-47,742,000	-44,232,000
Intangible assets, net	30,259,000	39,064,000
Amortization of intangible asset	6,200,000	11,600,000	9,600,000
Number of products no longer actively market	2
Impairment charges		1,300,000
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	1 year
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	15 years
Developed product technology [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	3 years
Developed product technology [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	8 years
Distribution rights [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	3 years
Distribution rights	$2,095,000	$2,343,000
Intellectual property [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	5 years
License agreements [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	1 year
License agreements [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	7 years
Core technology [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	10 years
Trademarks and trade names [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	3 years
Trademarks and trade names [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	9 years
Customer-related [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	12 years
Customer-related [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	15 years
Distribution network [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	10 years
Distribution network [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	12 years
Physician education programs [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	10 years
Supply agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	10 years

Balance_Sheet_Details_Future_E

Balance Sheet Details - Future Expected Amortization Expense Related to Intangible Assets (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]
2015	$5,646
2016	5,163
2017	4,866
2018	3,053
2019	2,852
Thereafter	8,679
Total future expected amortization expense	$30,259

Balance_Sheet_Details_Accrued_

Balance Sheet Details - Accrued Expenses (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]
Legal	$967	$2,139
Accounting	1,262	928
Severance	318	297
Restructuring	531	9,170
Sales milestones	107	1,828
Accrued taxes	1,344	1,120
Deferred rent	785	1,163
Royalties	2,129	2,347
Commissions	6,152	6,180
Payroll and related	8,291	9,369
Litigation settlements	7,393	22,600
Accrued interest	946	0
Other	5,168	5,855
Total accrued expenses	$35,393	$62,996

Balance_Sheet_Details_Schedule

Balance Sheet Details - Schedule of Changes in Carrying Amount of Goodwill (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Roll Forward]
Balance at January 1,	$183,004	$180,838
Change in Phygen goodwill	0	-1,610
Effect of foreign exchange rate on goodwill	-11,671	3,776
Balance at December 31,	$171,333	$183,004

License_and_Consulting_Agreeme1

License and Consulting Agreements - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Aug. 31, 2014

Oct. 31, 2013

Sep. 30, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Oct. 31, 2012

Jun. 30, 2009

Dec. 15, 2010

Dec. 31, 2013

Nov. 30, 2010

Dec. 31, 2007

Dec. 31, 2010

Feb. 28, 2009

Sep. 30, 2010

Jan. 31, 2010

Mar. 31, 2010

Nov. 30, 2012

Sep. 30, 2010

Jul. 31, 2014

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Royalty Rate

7.00%

Royalty Rate, Amended

8.50%

Royalty Obligation Per Year

$200,000

Royalty Accrual Reversal

1,700,000

Issuance of common stock

200,000

Cash payment

300,000

Amortization of acquired intangible assets

2,974,000

3,009,000

2,180,000

In process research and development expense ("IPR&D")

16,799,000

14,190,000

14,886,000

Provision for excess and obsolete inventory

3,539,000

11,652,000

6,658,000

In-process research and development

102,000

0

341,000

Supply agreement [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Up-front payment paid

1,000,000

Agreement term

7 years

Minimum purchase requirements

5,900,000

License Agreements [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Issuance of common stock

260,000

OsseoScrew License Agreement [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Milestone payments

1,500,000

3,600,000

Additional milestone payments

300,000

2,500,000

Issuance of common stock

1,000,000

1,000,000

Intangible assets

2,500,000

Cash payment

1,500,000

Intangible assets, amortization period

7 years

Number of shares of Common stock

452,488

Reversal of accrual for milestone payments

600,000

License Agreement with Helix Point, LLC [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Issuance of common stock

400,000

Intangible assets

200,000

200,000

Cash payment

200,000

Intangible assets, amortization period

7 years

Distribution Agreement with Parcell Spine, LLC [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Additional milestone payments

1,000,000

Issuance of common stock

1,000,000

1,000,000

Cash payment

500,000

500,000

Intangible assets, amortization period

7 years

Number of shares of Common stock

476,190

Amortization of acquired intangible assets

900,000

Addition in intangible assets

1,500,000

Provision for excess and obsolete inventory

2,600,000

Distribution Agreement with Parcell Spine, LLC [Member] | Research and Development Arrangement [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Issuance of common stock

1,000,000

Cash payment

1,000,000

In process research and development expense ("IPR&D")

2,000,000

Distribution Agreement with Parcell Spine, LLC [Member] | Initial Cash Payment [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

In process research and development expense ("IPR&D")

500,000

Distribution Agreement with Parcell Spine, LLC [Member] | Development Milestone Payments [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Number of shares of Common stock

465,116

License Agreement with R Tree Innovations LLC [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Issuance of common stock

200,000

500,000

Intangible assets

500,000

1,300,000

500,000

1,300,000

Cash payment

300,000

800,000

Intangible assets, amortization period

7 years

Number of shares of Common stock

367,044

Asset Purchase Agreement with National Medical Solutions, LLP [Member] [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments to Acquire in Process Research and Development

200,000

Stock Issued During Period, Shares, New Issues

72,992

Stock Issued During Period, Value, New Issues

100,000

In-process research and development

$300,000

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended	12 Months Ended			0 Months Ended	9 Months Ended	0 Months Ended					1 Months Ended	3 Months Ended
	Feb. 28, 2013	Sep. 30, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Aug. 30, 2013	Sep. 30, 2014	Nov. 21, 2014	Mar. 20, 2014	Mar. 17, 2014	Oct. 01, 2014	Apr. 10, 2014	Mar. 31, 2014	Dec. 31, 2014	Mar. 31, 2013	Jun. 07, 2012	Jul. 30, 2013
Line of Credit Facility [Line Items]
Maximum borrowing capacity																$50,000,000
Line of credit, repayment			156,106,000	168,855,000	99,853,000
Debt issuance costs					200,000
Less: debt discount			7,331,000	0	600,000									7,331,000
Borrowing capacity																40,000,000
Credit facility used to pay off its existing term loan					34,300,000
Early termination and other fees					2,300,000
Loss on extinguishment of debt costs		2,900,000
Up-front commitment fee					200,000
Debt default accrued interest rate			5.00%											5.00%
Line of credit facility amendment fee	100,000
Non-cash interest expense			300,000	200,000	900,000
Interest expense			5,300,000	3,600,000	2,600,000
Exercise price of warrants															2.5
Warrants value										5,700,000
Litigation settlement expense			0	45,982,000	0
Restricted cash			4,400,000	0										4,400,000
Long-term restricted cash			2,400,000											2,400,000
Capital leases maturity			Oct-17
Minimum [Member]
Line of Credit Facility [Line Items]
Capital leases interest percentage			6.60%											6.60%
Maximum [Member]
Line of Credit Facility [Line Items]
Capital leases interest percentage			9.60%											9.60%
Silicon Valley Bank [Member]
Line of Credit Facility [Line Items]
Line of credit, repayment					8,100,000
Existing line of credit					17,600,000
Working capital line of credit [Member]
Line of Credit Facility [Line Items]
Line of credit, balance			31,800,000											31,800,000
Line of credit, repayment			156,100,000
Line of credit, total amount drawn			163,100,000											163,100,000
Term loan [Member]
Line of Credit Facility [Line Items]
Line of credit, balance			28,600,000											28,600,000
Amended Credit Facilty with MidCap [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity			60,390,000	52,081,000		73,000,000								60,390,000			50,000,000
Line of credit, repayment						28,000,000
Term loan payments							300,000
Debt issuance costs						400,000
Less: debt discount						400,000
Amended Credit Facilty with MidCap [Member] | Term Loan Drawn On Closing [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity						33,000,000
Amended Credit Facilty with MidCap [Member] | Term Loan. Delayed Draw [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity						5,000,000
Amended Credit Facilty with MidCap [Member] | Credit Facility [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate			6.00%
Maximum borrowing capacity						40,000,000
Line of credit, balance			31,800,000											31,800,000
Line of Credit Facility, Interest Rate Description			LIBOR plus 6.0%
Interest rate of revolving line of credit			6.20%											6.20%
Amended Credit Facilty with MidCap [Member] | Term loan [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate			8.00%
Line of Credit Facility, Interest Rate Description			("LIBOR") plus 8.0%
Line of Credit Facility, Floor on Interest Rate, Percentage			9.50%
Interest rate of revolving line of credit			9.50%											9.50%
Deerfield [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity			26,000,000	0						50,000,000				26,000,000
Line of credit, balance								6,000,000	20,000,000
Net proceeds from draw under Facility Agreement								5,900,000
Aggregate amount of draw down for working capital										15,000,000
Increment amount of draw down for general corporate purposes										2,500,000
Transaction fee as percentage of principal amount										2.50%
Facility agreement stated interest rate										8.75%
Number of days following borrowing request to determine exercise price associated with each disbursement borrowing under facility agreement										15 days
Debt Issuance Cost								200,000	500,000
Number of warrants issued								1,200,000
Exercise price of warrants									1.39	1.39
Net proceeds from initial draw under Facility Agreement									19,500,000
Warrants value								900,000	4,700,000
Warrant amount reclassified as debt discount								200,000	2,300,000
Line of Credit Facility, Amount Outstanding			26,500,000											26,500,000
Equal annual payments			3
Deerfield [Member] | Warrants issued on March 17th [Member]
Line of Credit Facility [Line Items]
Number of warrants issued			6,250,000
Deerfield [Member] | Warrants issued on March 20th [Member]
Line of Credit Facility [Line Items]
Number of warrants issued			4,000,000
Deerfield [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights Associated with Each Disbursement Borrowing										10,000,000
Orthotec LLC, Litigation Settlement [Member]
Line of Credit Facility [Line Items]
Litigation settlement expense			18,600,000								1,100,000	15,750,000	1,750,000
Beginning October 2014 [Member] | Amended Credit Facilty with MidCap [Member]
Line of Credit Facility [Line Items]
Term loan payments														$500,000

Debt_Long_Term_Debt_Detail

Debt - Long -Term Debt (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 07, 2012	Aug. 30, 2013	Jul. 30, 2013	Mar. 17, 2014
Debt Instrument [Line Items]
Maximum borrowing capacity				$50,000,000
Note payable related to software license purchases	250,000	58,000
Financing agreements for premiums on insurance policies	1,580,000	1,427,000
Total	88,220,000	53,566,000
Add: capital leases (see Note 7)	1,784,000	1,336,000
Unamortized Debt Issuance And Debt Discount	-7,331,000	0	-600,000
Debt and Capital Lease Obligations	82,673,000	54,902,000
Less: current portion of long-term debt	-8,076,000	-4,924,000
Total long-term debt, net of current portion	74,597,000	49,978,000
Amended Credit Facilty with MidCap [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	60,390,000	52,081,000			73,000,000	50,000,000
Unamortized Debt Issuance And Debt Discount					-400,000
Deerfield [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$26,000,000	$0					$50,000,000

Debt_Principal_Payments_on_Deb

Debt - Principal Payments on Debt (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]
2015	$7,346
2016	54,874
2017	8,667
2018	8,667
2019	8,666
Thereafter	0
Total	88,220	53,566
Add: capital lease principal payments	1,784	1,336
Less: debt discount	7,331	0	600
Total	82,673
Current portion of long-term debt	8,076	4,924
Long-term debt, less current portion	$74,597	$49,978

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended				1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 08, 2014	Oct. 01, 2014	Apr. 10, 2014	Mar. 15, 2014	Mar. 31, 2014
Loss Contingencies [Line Items]
Rent expenses	$3,400,000	$3,800,000	$3,700,000
Litigation settlement expense	0	45,982,000	0
Healthpoint Capital [Member]
Loss Contingencies [Line Items]
Attorneys' fees paid by insurance carriers				5,250,000
Lease agreement [Member]
Loss Contingencies [Line Items]
Fixed annual rate	3.00%
Security deposit	293,200
Lease rent abated	38,480
Letter of credit issued for security deposit	2
Tenant improvement allowance	1,100,000
Lease agreement [Member] | First year [Member]
Loss Contingencies [Line Items]
Rent payable for leases	73,500
Lease agreement [Member] | Final year [Member]
Loss Contingencies [Line Items]
Rent payable for leases	93,000
Sublease [Member]
Loss Contingencies [Line Items]
Fixed annual rate	2.50%
Security deposit	93,500
Sublease [Member] | First year [Member]
Loss Contingencies [Line Items]
Rent payable final year of Sublease	80,500
Sublease [Member] | Final year [Member]
Loss Contingencies [Line Items]
Rent payable final year of Sublease	93,500
Orthotec LLC, Litigation Settlement [Member]
Loss Contingencies [Line Items]
Contractual claim settlement liability							49,000,000
Litigation settlement expense	18,600,000				1,100,000	15,750,000		1,750,000
Litigation settlement interest, quarterly installments, amount							1,100,000
Orthotec LLC, Litigation Settlement [Member] | Beginning Fourth Quarter of 2014 [Member]
Loss Contingencies [Line Items]
Contractual claim settlement liability							31,500,000
Litigation Settlement, Quarterly Installments, Amount							1,100,000
Litigation settlement interest rate							7.00%
Orthotec LLC, Litigation Settlement [Member] | Final Installment [Domain]
Loss Contingencies [Line Items]
Litigation settlement, quarterly installments, amount							$700,000

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Annual Lease Payments (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]
Operating leases 2015	$3,150
Operating leases 2016	1,829
Operating leases 2017	377
Operating leases 2018	73
Operating leases 2019	8
Operating leases Thereafter	0
Operating leases, Total	5,437
Capital leases 2015	846
Capital leases 2016	787
Capital leases 2017	347
Capital leases 2018	0
Capital leases 2019	0
Capital leases Thereafter	0
Capital leases, Total	1,980
Less: amount representing interest	-196
Present value of minimum lease payments	1,784	1,336
Current portion of capital leases	-730
Capital leases, less current portion	$1,054

Redeemable_Preferred_Stock_and1

Redeemable Preferred Stock and Stockholders' Equity - Additional Information (Detail) (USD $)	12 Months Ended	0 Months Ended
	Dec. 31, 2014	8-May-12	Dec. 31, 2013
		Tranche
Subsidiary, Sale of Stock [Line Items]
Redeemable preferred stock carrying value	$23,603,000		$23,603,000
Redeemable preferred stock authorized	20,000,000		20,000,000
Redemption value per share will be reported as dividend	$9
Eclipse Advisors, LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Commitment to purchase shares of common stock, amount, maximum		25,000,000
Term of investment agreement		24 months
Number of tranches to purchase common stock		2
Period for purchase common stock in two tranches		31 days
Percentage of common stock to be purchase on 16th day after date of put notice		50.00%
Percentage of common stock to be purchase on 31st day after date of put notice		50.00%
Percentage of volume weighted average price of common stock used to determine per share price		90.00%
Number of trading days taken for estimating shares for issuance		15 days
Maximum percentage of committed shares of common stock after sending cancellation notice		50.00%
Issuance of common stock		231,045
Commitment fee		500,000
Number of Trading Days Proceeding Investment Agreement Effective Date to Determine Commitment Fee		5 days
Redeemable Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Redeemable preferred stock carrying value	$23,600,000
Redeemable preferred stock authorized	20,000,000
Redeemable preferred stock, price per share	$7.11		$7.11
Redeemable preferred stock redemption, price per share	$9

Equity_Transactions_Equity_Tra2

Equity Transactions Equity Transactions - Additional Information (Details) (USD $)	3 Months Ended	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 21, 2014	Mar. 20, 2014	Mar. 17, 2014	Mar. 31, 2013	Jun. 07, 2012	Sep. 30, 2014
Class of Warrant or Right [Line Items]
Exercise price of warrants								2.5
Maximum borrowing capacity									$50,000,000
Warrants value							5,700,000
Other income (expense)		-33,000	-1,662,000	-794,000
Common stock warrant liabilities	8,702,000	8,702,000	0
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Risk-free interest rate	1.80%
Dividend yield	0.00%
Expected volatility	61.00%
Expected life (years)	5 years 3 months
Deerfield [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrants						1.39	1.39
Number of days following borrowing request to determine exercise price associated with each disbursement borrowing under facility agreement							15 days
Maximum borrowing capacity	26,000,000	26,000,000	0				50,000,000
Warrants value					900,000	4,700,000
Amount of draw down under Facility Agreement					6,000,000	20,000,000
Net proceeds from initial draw under Facility Agreement						19,500,000
Number of warrants issued					1,200,000
Net proceeds from draw under Facility Agreement					5,900,000
Warrant amount reclassified as debt discount					200,000	2,300,000
Warrants issued and outstanding										11,450,000
Other income (expense)		$2,600,000
Maximum [Member] | Deerfield [Member]
Class of Warrant or Right [Line Items]
Number of securities called by warrants associated with each disbursement borrowing							10,000,000
Warrants issued on March 20th [Member] | Deerfield [Member]
Class of Warrant or Right [Line Items]
Number of warrants issued		4,000,000
Warrants issued on March 17th [Member] | Deerfield [Member]
Class of Warrant or Right [Line Items]
Number of warrants issued		6,250,000

Stock_Benefit_Plans_and_StockB2

Stock Benefit Plans and Stock-Based Compensation - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended			1 Months Ended
	Nov. 19, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	31-May-13	Dec. 31, 2011	Jul. 31, 2014	Oct. 31, 2013	Mar. 31, 2013
								payment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance		25,263,000
Percentage of award vesting on the first anniversary	33.33%
Purchase of common stock shares for issuance of warrants									500,000
Exercise price of warrants									2.5
Warrants expiration date		March 1, 2015
Common stock issued		97,599,000	96,703,000
Stock based compensation		$4,554,000	$4,078,000	$3,690,000
Media Advertising Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Consulting fees paid			200,000		200,000
Stock based compensation		700,000	1,100,000
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase of common stock shares for issuance of warrants				93,750
Exercise price of warrants				1.6
Credit facility, finance charges						200,000
Term of warrants						10 years
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock options granted		$0.81	$1.09	$1.10
Closing stock price		$1.41
Unrecognized compensation expense for stock options and awards expected to be recognized		7,500,000
Straight-line basis over a weighted average period		2 years 6 months
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance		690,000
Weighted average fair value of awards granted		$1.32	$1.97	$1.57
Non-Option equity instruments, grant date fair value		$1.60	$1.88
Performance-based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-Option equity instruments, grant date fair value		$1.42	$0
Registered shares [Member] | Media Advertising Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued			500,000		225,000
Unregistered shares [Member] | Media Advertising Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued			352,000
2005 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance		15,800,000
Exercise price of incentive stock options, percent (less than 110%)		100.00%
Exercise price of option granted to stock holder, percent		10.00%
Exercise price of stock options granted to 10 percent stockholder , percent		110.00%
Shares of common stock remained available for issuance		3,400,000
2005 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options voting rights, percentage (more than 10%)		10.00%
2005 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted expiration term		10 years
2005 Plan [Member] | Incentive stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted expiration term		5 years
Share based payment award options, vesting period		4 years
2005 Employee, Director and Consultant Stock Plan [Member] | Performance-based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-Option equity instruments, granted shares							932,000
Non-Option equity instruments, grant date fair value							$1.42
2005 Employee, Director and Consultant Stock Plan [Member] | Performance-based Restricted Stock Units [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage							0.00%
2005 Employee, Director and Consultant Stock Plan [Member] | Performance-based Restricted Stock Units [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage							200.00%
Collaborative Arrangement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Collaborative arrangement term								3 years
Collaborative arrangement, number of periodic payments								3
Collaborative arrangement, periodic payment aggregate amount								$8,000,000
Collaborative payments, per share price								$1.95
Number of days leading up to and including date of signing collaboration agreement for per share price used to calculate annual payments to collaborator								5 days
Number of months of services provided for number of shares issued used to calculate annual payments to collaborator								12 months
Common stock issued		1,456,035

Stock_Benefit_Plans_and_StockB3

Stock Benefit Plans and Stock-Based Compensation - Summary of Stock Option Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Shares Outstanding, Beginning balance	7,761
Shares, Granted	2,019
Shares, Exercised	-21
Shares, Forfeited	-1,492
Shares Outstanding, Ending balance	8,267	7,761
Shares, Options vested and exercisable	4,149
Shares, Options vested and expected to vest	7,819
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price, Outstanding, Beginning balance	$2.23
Weighted average exercise price, Granted	$1.42
Weighted average exercise price, Exercised	$1.33
Weighted average exercise price, Forfeited	$1.99
Weighted average exercise price, Outstanding, Ending balance	$2.08	$2.23
Weighted average exercise price, Options vested and exercisable	$2.46
Weighted average exercise price, Options vested and expected to vest	$2.11
Weighted average remaining contractual term (in years), Outstanding, balance	7 years 4 months 6 days	7 years 7 months 2 days
Options vested and exercisable at December 31, 2014, Weighted average remaining contractual term (in years)	6 years 1 month 27 days
Options vested and expected to vest at December 31, 2014, Weighted average remaining contractual term (in years)	7 years 3 months 3 days
Aggregate intrinsic value, Outstanding, Beginning balance	$753
Aggregate intrinsic value, Granted	0
Aggregate intrinsic value, Exercised	0
Aggregate intrinsic value, Forfeited	0
Aggregate intrinsic value, Outstanding, Ending balance	71	753
Aggregate intrinsic value, Options vested and exercisable	27
Aggregate intrinsic value, Options vested and expected to vest	$64

Stock_Benefit_Plans_and_StockB4

Stock Benefit Plans and Stock-Based Compensation - Summary of Information about Restricted Stock Awards Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Common stock reserved for future issuance	25,263,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares, Unvested beginning balance	807,000
Shares, Awarded	493,000
Shares, Vested	-155,000
Shares, Forfeited	-455,000
Shares, Unvested ending balance		807,000
Common stock reserved for future issuance	690,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, Unvested beginning balance	$1.88
Weighted average grant date fair value, Awarded	$1.32
Weighted average grant date fair value, Vested	$2.25
Weighted average grant date fair value, Forfeited	$1.57
Weighted average grant date fair value, Unvested ending balance	$1.60	$1.88
Weighted average remaining recognition period (in years), Unvested beginning balance	1 year 9 months 29 days	2 years 3 months 18 days
Weighted average remaining recognition period (in years), Unvested ending balance	1 year 9 months 29 days	2 years 3 months 18 days
Performance-based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares, Unvested beginning balance	0
Shares, Awarded	932,000
Shares, Vested	0
Shares, Forfeited	-78,000
Shares, Unvested ending balance	854,000	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, Unvested beginning balance	$0
Weighted average grant date fair value, Awarded	$1.42
Weighted average grant date fair value, Vested	$0
Weighted average grant date fair value, Forfeited	$0
Weighted average grant date fair value, Unvested ending balance	$1.42	$0
Weighted average remaining recognition period (in years), Unvested beginning balance	2 years	0 days
Weighted average remaining recognition period (in years), Unvested ending balance	2 years	0 days

Stock_Benefit_Plans_and_StockB5

Stock Benefit Plans and Stock-Based Compensation - Summary Common Stock Reserved for Future Issuance (Detail)	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance	25,263,000
Stock options outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance	8,267,000
Performance restricted stock unit issued and outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance	854,000
Warrants outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance	12,044,000
Authorized for future grant under 2005 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance	3,408,000

Income_Taxes_Components_of_Pre

Income Taxes - Components of Pretax Loss from Operations (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
U.S. Domestic	($8,106)	($9,264)	($3,310)
Foreign	-3,689	-69,784	-13,308
Pretax loss from operations	($11,795)	($79,048)	($16,618)

Income_Taxes_Components_of_Ben

Income Taxes - Components of (Benefit) Provision for Income Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current:
Federal	$0	($21)	$107
State	145	186	24
Foreign	526	2,525	2,083
Total current provision (benefit)	671	2,690	2,214
Deferred:
Federal	238	229	137
State	24	15	29
Foreign	154	245	-3,539
Total deferred provision (benefit)	416	489	-3,373
Total provision (benefit)	$1,087	$3,179	($1,159)

Income_Taxes_Schedule_of_Effec

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Federal statutory rate	-35.00%	-35.00%	-35.00%
Adjustments for tax effects of:
State taxes, net	-1.10%	-0.10%	0.00%
Stock-based compensation	6.20%	0.50%	-0.50%
Foreign taxes	3.40%	1.10%	-0.10%
Tax credits	-3.30%	-0.40%	-0.70%
Deemed foreign dividend	0.00%	0.00%	0.20%
Fair market value adjustments	-7.60%
Intercompany debt forgiveness and other permanent adjustments	3.10%	9.50%	5.00%
Tax rate adjustment	0.40%	0.20%	0.70%
Uncertain tax positions	5.30%	2.70%	14.90%
Other	0.20%	-0.40%	3.30%
Valuation allowance	37.50%	25.90%	5.20%
Effective income tax rate	9.10%	4.00%	-7.00%

Income_Taxes_Significant_Compo

Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Allowances and reserves	$818	$816
Accrued expenses	3,674	3,685
Inventory reserves	8,532	7,549
Net operating loss carryforwards	41,965	26,497
Property and equipment	1,976	1,171
Stock-based compensation	2,168	2,769
Legal settlement	1,204	17,998
Income tax credit carryforwards	2,218	1,800
Total deferred tax assets	62,555	62,285
Valuation allowance	-58,781	-56,690
Total deferred tax assets, net of valuation allowance	3,774	5,595
Deferred tax liabilities:
Property and equipment	0	0
Intangible assets	2,881	4,806
Goodwill	1,518	1,256
Total deferred tax liabilities	4,399	6,062
Net deferred tax assets (liabilities)	($625)	($467)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax [Line Items]
Deferred tax asset, valuation allowance	$58,781,000	$56,690,000
Deferred tax liabilities, goodwill	1,518,000	1,256,000
Number of years cumulative pre-tax loss	3 years
Deferred tax assets and recognized tax benefit		1,400,000
Unrecognized tax benefits	8,861,000	7,835,000	5,897,000	4,197,000
Uncertain tax benefits that, if realized, would affect the effective tax rate	8,100,000
Accrued interest and penalties	1,300,000
Operating loss carryforwards federal	56,600,000
Operating loss carryforwards state	45,500,000
Federal and state net operating loss carryforwards, expiring year	2034
Federal research and development tax credits	3,100,000
State research and development tax credits	2,800,000
Operating loss carryforwards foreign	$84,600,000
Foreign net operating loss carryforward expiration year	2018
Federal research and development tax credits [Member]
Income Tax [Line Items]
Federal research and development tax credits expiration year	2034

Income_Taxes_Summary_of_Change

Income Taxes - Summary of Changes to Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, Beginning Balance	$7,835	$5,897	$4,197
Additions based on tax positions related to the prior year	391	221	987
Additions based on tax positions related to the current year	1,050	1,664	743
Reductions as a result of lapse of applicable statute of limitations	-40	-20	-58
Additions as a result of foreign exchange rates and other		73	28
Reductions as a result of foreign exchange rates and other	375
Unrecognized tax benefits, Ending Balance	$8,861	$7,835	$5,897

Segment_and_Geographical_Infor2

Segment and Geographical Information - Additional Information (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
									Location	Location	Location
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of reportable business segment									1
Number of geographic regions									2	2	2
Revenues	$53,627	$51,013	$53,167	$49,173	$53,065	$50,196	$51,020	$50,443	$206,980	$204,724	$196,278
Maximum percentage of revenues										10.00%	10.00%
Minimum percentage of revenues									10.00%
Japan [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									$31,900	$28,000	$28,600
Maximum percentage of revenues									10.00%
Minimum percentage of revenues										10.00%	10.00%

Segment_and_Geographical_Infor3

Segment and Geographical Information - Schedule of Revenues Attributed to Geographic Location (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting, Revenue Reconciling Item [Line Items]
Total consolidated revenues	$53,627	$51,013	$53,167	$49,173	$53,065	$50,196	$51,020	$50,443	$206,980	$204,724	$196,278
UNITED STATES
Segment Reporting, Revenue Reconciling Item [Line Items]
Total consolidated revenues									137,060	134,951	130,476
International [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total consolidated revenues									$69,920	$69,773	$65,802

Segment_and_Geographical_Infor4

Segment and Geographical Information - Schedule of Long Lived Assets by Geographical Areas (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]
Total consolidated assets	$344,923	$365,630
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Total consolidated assets	200,978	196,383
International [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total consolidated assets	$143,945	$169,247

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Related Party Transaction [Line Items]
Indemnification obligations	$0.10	$1.70
Healthpoint Capital [Member]
Related Party Transaction [Line Items]
Payable liability	$0.20	$0.20	$0.20

Retirement_Plan_Additional_Inf

Retirement Plan - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Defined Benefit Plan Disclosure [Line Items]
Matching contributions by employer	4.00%
Employer matching contribution, vesting period	1 year
Section 401(k) plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Total contributions	$0.60	$0.60	$0.50

Restructuring_Activities_Addit

Restructuring Activities - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restructuring and Related Activities [Abstract]
Restructuring expenses	$706,000	$9,665,000	$0
Restructuring accrual	531,000	9,170,000
Additional inventory reserve recorded	$4,900,000

Restructuring_Activities_Restr

Restructuring Activities Restructuring Activities - Movement of Restructuring Reserve (Details) (USD $)	12 Months Ended			15 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$706	$9,665	$0
Restructuring, paid and other	-9,345
Restructuring accrual	531	9,170		531
Restructuring total costs incurred				10,371
Social Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	197
Restructuring, paid and other	-8,836
Restructuring accrual	531	9,170		531
Restructuring total costs incurred				9,450
Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	509
Restructuring, paid and other	-509
Restructuring accrual	0	0		0
Restructuring total costs incurred				$921

Cross_Medical_Additional_Infor

Cross Medical - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended
In Millions, unless otherwise specified	Aug. 02, 2012	Jan. 31, 2012	Dec. 31, 2014
	Installment
Guarantees And Letters Of Credit [Line Items]
Initial payment towards settlement		$5
Number of quarterly payments	13
Contractual obligations, due in 2015			3
Thirteen quarterly payments [Member]
Guarantees And Letters Of Credit [Line Items]
Initial payment towards settlement	1

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail) (USD $)	3 Months Ended												12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013		Sep. 30, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Revenue	$53,627	$51,013	$53,167	$49,173	$53,065		$50,196		$51,020		$50,443		$206,980	$204,724	$196,278
Gross profit	37,690	36,306	36,120	33,294	35,255		24,232		32,093		32,742		143,410	124,322	123,768
Total operating expenses	34,717	34,574	34,279	37,996	91,257		37,406		34,992		34,100		141,566	197,755	133,605
Net loss	($273)	($3,041)	($2,895)	($6,673)	($60,407)		($14,510)		($4,661)		($2,649)		($12,882)	($82,227)	($15,459)
Net loss per basic share (in dollars per share)	$0	($0.03)	($0.03)	($0.07)									($0.13)	($0.85)	($0.17)
Net loss per diluted share (in dollars per share)	($0.03)	($0.04)	($0.03)	($0.07)									($0.16)	($0.85)	($0.17)
Net loss per basic and diluted share (in dollars per share)					($0.62)	[1]	($0.15)	[1]	($0.05)	[1]	($0.03)	[1]
[1]	Basic and diluted net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal the total for the year.

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Allowance for Doubtful Accounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance Beginning	$1,048	[1]	$1,074	[1]	$1,055	[1]
Provision	522	[1]	404	[1]	859	[1]
Write-offs and recoveries, net	-777	[1]	-430	[1]	-840	[1]
Balance Ending	793	[1]	1,048	[1]	1,074	[1]
Reserve for Excess and Obsolete Inventories [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance Beginning	23,946	[2]	17,222	[2]	13,174	[2]
Provision	3,539	[2]	11,652	[2]	6,658	[2]
Write-offs and recoveries, net	-6,160	[2]	-4,928	[2]	-2,610	[2]
Balance Ending	$21,325	[2]	$23,946	[2]	$17,222	[2]
[1]	The provision is included in selling expenses.
[2]	The provision is included in cost of revenues.